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I. ABBREVIATIONS 
ACE2 angiotensin-converting enzyme 2 
ADE antibody-dependent enhancement 
APC antigen-presenting cell 
ARDS acute respiratory distress syndrome 
Bcl-2 B-cell lymphoma 2 
BSA bovine serum albumin 
CAM chorioallantois membranes 
CD cluster of differentiation 
CDC Centers for Disease Control and Prevention 
CEF chicken embryonic fibroblasts 
CO2 carbon dioxide 
COVID-19 coronavirus disease 2019 
CSG Coronaviridae Study Group 
DAI double-stranded RNA activated inhibitor of translation 
DAPI 4′,6-Diamidin-2-phenylindol 
ddH2O double-distilled water 
DMEM Dulbecco`s modified Eagle`s medium 
DMSO dimethyl sulfoxide 
DNA deoxyribonucleic acid 
dNTP deoxynucleosidtriphosphate 
DPBS Dulbecco`s phosphate buffered saline 
dsRNA double-stranded RNA 
EBV Epstein–Barr virus 
EDTA ethylene-diamine tetraacetate 
eIF2α eukaryotic initiation factor-2α 
ELISA enzyme-linked immunosorbent assay 
ELISpot enzyme-linked immunosorbent spot assay 
ER endoplasmic reticulum 
ERD enhanced respiratory infection 
ERGIC endoplasmic reticulum Golgi intermediate complex 
EV extracellular virion 
FACS    fluorescence-activated cell sorting 
FBS fetal bovine serum 
FDA Food and Drug Agency 
I. Abbreviations VIII 
FP fusion protein 
GPT glutamate-pyruvate-transaminase 
hpi hours post infection 
HA  hemagglutinin 
HEPES N-(2-Hydroxyethyl)-piperazin-N′-(2-ethansulfonsäure) 
HIV human immunodeficiency virus 
HR heptat repeat 
HRP horseradish peroxidase 
IC50 half maximal inhibitory concentration 
ICS intracellular cytokine staining 
ICU intensive care unit 
IEDB Immune Epitope Database 
i.m. intramuscular 
IMV intracellular mature virus  
IFA Immunofluorescence assay 
IFN interferon 
Ig immunoglobulin  
IL interleukin 
IRF interferon regulatory factor  
I.T. intracellular tail 
kDa kilodalton 
kb kilo base pairs 
LB lysogeny broth 
l liter 
M Mol 
MEM minimal essential medium 
MHC major histocompatibility complex 
mg milligram 
min minute 
ml milliliter 
mM millimol 
MOI multiplicity of infection 
MVA Modified Vaccinia virus Ankara 
MVA-SARS-CoV-2-S/ 
MVA-S  
Modified Vaccinia virus Ankara expressing severe acute 
respiratory syndrome coronavirus 2 spike protein 
NF-κB nuclear factor kappa-light-chain-enhancer of activated B 
cells 
I. Abbreviations IX 
nsp non-structural protein 
NTD N-terminal domain 
OD optical density 
o/n over night 
PBS(T) phosphate buffered saline (tween20) 
PCR polymerase chain reaction 
PFU plaque-forming units 
PMA phorbol 12-myristate 13-acetate 
PNGase F peptide-N-glycosidase F 
PUMA p53 upregulated modulator of apoptosis 
RBD receptor-binding domain 
RdRp-complex RNA-dependent RNA polymerase complex 
RNA ribonucleic acid 
rpm revolutions per minute 
RPMI Roswell Park Memorial Institute 
RPV Rinderpest virus 
RT room temperature 
RT-PCR reverse transcription polymerase chain reaction 
SARS-CoV-2 severe acute respiratory syndrome coronavirus 2 
SDS-PAGE sodium dodecyl sulfate polyacrylamide gel electrophoresis 
sec second 
SFC spot-forming cells 
T.A. transmembrane anchor 
TAE tris-acetate-EDTA 
TBS tris-buffered saline 
TCID50 tissue culture infection dose 50 
TCR T cell receptor 
Th T helper 
TMB 3,3′,5,5′-Tetramethylbenzidin 
TNF-α tumor necrosis factor alpha 
UV ultraviolet  
V volt, volume 
VNT virus neutralization assay 
VP-SFM virus production serum-free medium 
VSV vesicular stomatitis virus 
WB Western Blot 
WHO World Health Organization 
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II. INTRODUCTION 
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the 
causative pathogen of the global pandemic coronavirus disease 2019 (COVID-
19). Due to an extremely efficient human-to-human transmission, a global 
spread of SARS-CoV-2 occurred within months, since affecting the daily life of 
millions of individuals. Many infections are asymptomatic or show mild 
symptoms and the estimated case fatality rate of 2-5% is lower than for 
infections with other coronaviruses, such as SARS-CoV-1 (~10%) (WHO 
2021c) or MERS-CoV (~34 %) (WHO 2019). Nevertheless, cases of long-
lasting diseases following a COVID-19 infection (long-COVID, post-COVID or 
chronic COVID) are described, affecting symptomatic and asymptomatic 
patients. The use of vaccines is the best option to halt the global threat of SARS-
CoV-2 and vaccine research started at an unprecedented speed. One year after 
the emergence of COVID-19, more than 65 SARS-CoV-2 specific vaccine 
candidates are in clinical trials. By the end of February 2021, two mRNA-based 
vaccines and one replication-deficient adenoviral vector vaccine are already 
licensed for immunization in Europe.  Herby, the SARS-CoV-2 spike (S) protein 
is the key antigen for vaccine development. Efficient activation of humoral and 
cell-mediated immune responses is the expected basis of protective 
vaccination.  
 
The aim of this project was the generation and characterization of recombinant 
Modified Vaccinia virus Ankara (MVA) as a new COVID-19 candidate vaccine. 
In cell culture infections, the recombinant virus demonstrated high levels of 
genetic stability, efficient synthesis of SARS-CoV-2 S protein and a growth 
capacity suitable for vaccine production at industrial scale. S protein-specific 
humoral and cell-mediated immune responses were activated in BALB/c mice 
following vaccination with two different doses and two different vaccination 
schedules. These results contributed to a better understanding of spike antigen 
specific immune responses and strongly supported the further development of 
recombinant MVA as vaccine against SARS-CoV-2. 
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III. LITERATURE REVIEW 
1. SARS-CoV-2: an emerging pathogen 
1.1. Year 2020: Beginning of a global pandemic 
On December 13th, 2019, a novel virus invaded the human population (VOLZ et 
al. 2020), leading to a global pandemic within a few months. The first confirmed 
cases were reported at a seafood market in Wuhan (China) and the new agent 
spread throughout the world by travelers and community-based contacts (LI et 
al. 2020; ZHU et al. 2020). On February 11th, 2020, the new virus was named 
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by the 
Coronaviridae Study Group (CSG) of International Committee on Taxonomy of 
Viruses (CORONAVIRIDAE STUDY GROUP OF THE INTERNATIONAL 
COMMITTEE ON TAXONOMY OF VIRUSES. 2020; HU et al. 2020). The 
disease caused by this agent was named coronavirus infectious disease 2019 
(COVID-19) (SUN et al. 2020b) and on March 11th, 2020, COVID-19 was 
declared as a global pandemic by the World Health Organization (WHO) 
(SONG et al. 2020). Phylogenetic analysis showed relations to severe acute 
respiratory syndrome corona virus 1 (SARS-CoV-1) and Middle East respiratory 
syndrome coronavirus (MERS-CoV), both leading to smaller outbreaks in 2003 
and 2012, respectively (DROSTEN et al. 2003; ZAKI et al. 2012; ZHONG et al. 
2003; KSIAZEK et al. 2003). By the end of February 2021, one year after the 
first outbreak of COVID-19, more than 100 million global cases were confirmed 
with more than 2 million deaths. Globally, the United States, India and Brazil 
are the countries with the highest number of confirmed cases (JHU 2021). 
1.2. Taxonomy and viral life cycle 
SARS-CoV-2 is an enveloped, single-stranded RNA virus with a genome size 
of about 26 to 32 kb (CORONAVIRIDAE STUDY GROUP OF THE 
INTERNATIONAL COMMITTEE ON TAXONOMY OF VIRUSES. 2020; LU et 
al. 2020). The new virus is classified as a member of the order Nidovirales, 
family Coronaviridae, and subfamily Orthocoronavirinae (LAI et al. 2020; LU et 
al. 2020; WOO et al. 2012) (Figure 1). Coronaviruses are found commonly 
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among mammals (including humans) and birds causing a variety of different 
infectious diseases such as respiratory, gastro-intestinal, hepatic or 
neurological disorders (GUY et al. 2000; SIDDELL et al. 2008). Since 2020, 
seven different coronavirus species are known to cause illnesses in humans.  
 
 
Figure 1: Classification of the seven human pathogenic coronaviruses. New SARS-CoV-2 belongs 
to the order Nidovirales, family Coronaviridae, subfamily Orthocoronavirinae, genus β- Coronavirus, 
subgenus Sarbecovirus. Adapted from (Malik 2020). 
 
Four human α- and β-coronaviruses (HCoV-229E, HCoV-OC43, HCoV-NL63, 
and HCoV-HKU1) mainly cause cold-like symptoms, especially in 
immunocompromised individuals and children (GREENBERG 2016; PENE et 
al. 2003; VABRET et al. 2003; WOO et al. 2005), whereas the other three 
human β-coronaviruses, MERS-CoV, SARS-CoV-1 and SARS-CoV-2 are 
connected to severer illnesses (CUI et al. 2018).  
 
Members of the family Coronaviridae, including SARS-CoV-2, encode four 
structural proteins: spike (S) protein, nucleocapsid (N) protein, membrane (M) 
protein and the envelope (E) protein (Figure 2). Furthermore, six-teen non-
structural proteins (nsp 1-16) involved in different regulatory processes (e.g., 
formation of replicase transcriptase complex) have also been identified 
(KHAILANY et al. 2020). 
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The envelope protein is a very small, membrane integral protein with 8.4-12.0 
kDa in size, (KUO et al. 2006; SCHOEMAN and FIELDING 2019) which is 
structured into three main parts: a small hydrophilic amino (N) - terminus (7-12 
amino acids), a large hydrophobic transmembrane domain (25 amino acids) 
and a hydrophilic carboxyl (C) - terminus (CORSE and MACHAMER 2000; 
LIAO et al. 2006). The E protein is predominantly found in the endoplasmic 
reticulum and the Golgi complex, supporting the viral assembly and trafficking 
of infectious virions (CORSE and MACHAMER 2000; OPSTELTEN et al. 1995).  
 
The nucleocapsid protein is phosphorylated and associated with the viral RNA, 
by capsuling the genomic material within the viral particles. The N protein 
contains two RNA-binding domains (N-terminal and C-terminal domain) 
connected with a serine/arginine rich linkage region. Due to the high amount of 
positively charged amino acids, it is able to bind to the viral RNA (HUANG et al. 
2004; HURST et al. 2009; SAIKATENDU et al. 2007). The membrane protein 
with about 25-30 kDa in size has three transmembrane domains 
(ARMSTRONG et al. 1984), an N-terminal ectodomain and a C-terminal 
endodomain. The M protein is responsible for the shape of the virion and 
maintains the membrane curvature. Furthermore, the M protein is able to bind 
Figure 2: Structure of new SARS-CoV-2. Left: 3D structure of SARS-CoV-2. Right: SARS-CoV-2 
encodes four structural proteins: spike (S) protein (green), membrane (M) protein (red), envelope (E) 
protein (yellow) and nucleocapsid (N) protein (light blue) capsuling the viral RNA (dark blue). Created with 
BioRender.com  
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to the nucleocapsid protein (NAL et al. 2005). 
 
The spike glycoprotein is around 150 kDa in size and highly N-glycosylated. It 
is located as a trimer on the surface of the virion showing a crown-like (“corona”) 
appearance (BELOUZARD et al. 2012) (Figure 3).  
 
 
Figure 3: Structural analysis of SARS-CoV-2 spike (S) protein. The S protein consists of two subunits, 
S1 and S2, which are cleaved at a furine cleavage site during the entry of the host cell. The S1 subunit 
contains an N-terminal domain (NTD) and the receptor-binding domain (RBD). The S2 subunit contains 
the fusion protein (FP), a heptad repeat 1 (HR1), a heptad repeat 2 (HR2), a transmembrane anchor (T.A.) 
and an intracellular tail (I.T). Created with BioRender.com 
 
The full-length S protein subsists in a metastable pre-fusion conformation, 
undergoing structural rearrangement to unite with the host cell membrane 
(BOSCH et al. 2003; LI 2016). Upon entry to the host cell, cleavage at a furine 
cleavage site is mediated by host cell proteases, splitting full-length spike 
protein into the S1 and S2 subunit. The S1 subunit is responsible for receptor 
binding, whereas the S2 subunit helps to maintain the structure of the S protein 
(ABRAHAM et al. 2004; LUYTJES et al. 2004; GROOT et al. 2005). Within the 
S1 subunit, the receptor-binding domain (RBD) is able to bind to the human 
angiotensin-converting enzyme 2 (ACE2) receptor with its receptor-binding 
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motif (RBM). The ACE2 receptor is broadly distributed in various tissue cells, 
including heart, testis and intestine. There, ACE2 has a regulatory function to 
maintain heart or kidney function or control the blood pressure (LI et al. 2005; 
LI et al. 2003; LUAN et al. 2020). 
 
The entry of SARS-CoV-2 relies on an interplay between the virion and the host 
cell (Figure 4). The viral particles interact with specific proteins that are found 
on the surface of the host cell. The spike protein plays an important role in this 
early stage of infection by facilitating receptor binding and fusion with the host 
cell membrane. After binding to the ACE2 receptor, the envelope protein fuses 
with the cell membrane, introducing the viral RNA genome into the host cell 
(BELOUZARD et al. 2012; SHANG et al. 2020; ZHOU et al. 2020). The RNA 
genome is translated into polypeptides by the host cell translation machinery 
and they are cleaved into non-structural proteins, including components to form 
the RNA-dependent RNA polymerase (RdRp) complex (HARTENIAN et al. 
2021). The RdRp complex (nsp 12) generates a negative-sense genome and 
RNAs, which serve as templates to synthesize positive-sense progeny 
genomes and mRNAs (SAWICKI and SAWICKI 2005). Some of these mRNAs 
are translated into accessory and structural proteins which are studded on the 
endoplasmic reticulum - Golgi intermediate compartment (ERGIC), a mobile 
compartment responsible for trafficking between endoplasmic reticulum (ER) 
and Golgi complex (APPENZELLER-HERZOG and HAURI 2006). The positive-
sense RNA is capsulated by the nucleocapsid protein and incorporated into the 
ERGIC. The enveloped virion is formed and released from the infected host cell 
by exocytosis (HARTENIAN et al. 2021).  
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Figure 4: Replication cycle of SARS-CoV-2. Cell entry is mediated by the spike protein (1) binding to 
the ACE2 receptor. The RNA genome is released into the host cell (2) and translated into polypeptides. 
The polyproteins are cleaved into non-structural proteins (nsps) and the negative-sense RNA is 
transcribed (4), serving as a template to transcribe the positive-sense RNA (5). The subgenomic mRNA 
is translated into the structural proteins (spike protein, membrane protein and envelope protein) and other 
accessory proteins (6). These proteins are studded on the ERGIC, where the nucleocapsid protein (+ viral 
RNA) is budding (7). The virions are formed (8) and released via exocytosis (9) (HARTENIAN et al. 2021). 
Created with BioRender.com 
1.3. Clinical manifestations 
SARS-CoV-2 is mainly transmitted via droplets during the contact between 
infected and uninfected individuals. The main routes of transmission are 
coughing, sneezing, spitting or talking. Other routes were also observed, 
including sweat, stool, urine, and respiratory secretions (DING et al. 2004; 
PRAJAPAT et al. 2020; ZAYAS et al. 2012). The infection is caused by the 
contact of infectious droplets with the mucous membranes of eyes, nose and 
mouth (DU et al. 2020; WANG et al. 2020b).  
 
COVID-19 is classified into three categories, depending on the severity of the 
illness: mild, severe and critical (CHEN et al. 2020b; HUANG et al. 2020; TIAN 
et al. 2020; WU and McGOOGAN 2020). The most common symptoms of 
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COVID-19 are fever, cough, shortness of breath, headache, confusion, 
olfactory and taste disorder. Furthermore, many patients develop severe lung 
disease, causing the acute respiratory distress syndrome (ARDS) and 
inflammatory mediator associated airway inflammation. These syndromes 
result in impaired alveolar oxygenation and hypoxemia (CALABRESE et al. 
2020; CHEN et al. 2020a; TIAN et al. 2020). Other severe complications are 
metabolic acidosis, multiple organ failure or acute cardiac failure (HUANG et al. 
2020). Moreover, about 26% of SARS-CoV-2 infected patients end up at the 
intensive care unit (ICU), and elderly or patients with pre-existing illnesses have 
a poor prognosis (DENG and PENG 2020). Severe events developed by 
patients at the ICU include pneumonia and a so-called cytokine storm, driven 
by an over activation of the immune system. Multiple cytokines (IL-6, IL-10, IFN-
γ, TNF-α) could be detected at high amounts in the plasma of those patients 
(GAO et al. 2020; SPADARO et al. 2019).  
 
Although the range of symptoms is broad, and up to now, several millions of 
individuals have been infected with SARS-CoV-2, most cases follow mild 
symptoms and patients recover within a few days or weeks. Nevertheless, 
cases of long-term effects (post-COVID, chronic COVID, or long-COVID) were 
reported in the last couple of months, affecting both asymptomatic and 
symptomatic patients. As SARS-CoV-2 can infiltrate every organ, various long-
term effects were observed, including lung and neuronal injury (BOURGONJE 
et al. 2020; WANG et al. 2020a).  
1.4. Treatment and prevention 
Currently, no treatments are available and therefore, only supportive care is 
possible. There are various guidelines recommending treatments against 
COVID-19 such as bed rest with caloric intake, oxygen therapy via face mask, 
antiviral treatment (ribavirin, remdesivir, lopinavir/ritonavir, IFN-α, 
(hydroxy)chloroquine), plasmapheresis or immunotherapy (tocilizumab) (CHEN 
et al. 2020c; KLUGE et al. 2021).  
 
Lopinavir/ritonavir are mainly used in patients with less severe syndromes 
during the early stage of infection. The drugs inhibit protease enzymes and were 
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used successfully against MERS-CoV and SARS-CoV-1 (CHUNG et al. 2020; 
GUL et al. 2020). Although used in the clinics, a randomized study in 2020 with 
199 SARS-CoV-2 infected patients showed no significant difference between 
control group and treated group (CAO et al. 2020).  
 
Remdesivir was used during the Ebola outbreaks in Africa and patients with 
moderate and/or severe symptoms of COVID-19 are currently treated with this 
drug (ANTINORI et al. 2020). The substance targets the viral replication and is 
approved by the Food and Drug Agency (FDA) for clinical use (CHUNG et al. 
2020). A randomized study with 1,063 patients showed promising results, as 
the progression of COVID-19 could be stopped, and the recovery time could be 
shortened (BEIGEL et al. 2020). 
 
Moreover, anti-inflammatory drugs are used as treatments for COVID-19 
patients, as many patients with severe symptoms develop abnormal immune 
responses with high release of cytokines (e.g., IL-6, TNF-α or INF-γ) (GAO et 
al. 2020; SPADARO et al. 2019). Tocilizumab, a monoclonal antibody directed 
against the IL-6 receptor, was tested in several multicenter studies and showed 
an improvement of clinical syndromes (LUO et al. 2020; XU et al. 2020). 
 
Chloroquine and hydroxychloroquine show anti-inflammatory and anti-viral 
efficacy in patients suffering from rheumatic diseases or Malaria (KRAFTS et 
al. 2012). Both drugs inhibit the entry of SARS-CoV-2 and interfere with the 
glycosylation of the ACE2 receptor. The FDA approved an emergency use of 
chloroquine and hydroxychloroquine for severe cardiac events (CHUNG et al. 
2020). However, several multicenter studies were performed to test these drugs 
in COVID-19 patients for treatment and prophylaxis with no benefit for the 
patients (IBÁÑEZ et al. 2020; MÉGARBANE 2021).  
 
Although several promising drugs and treatments are available, prevention of 
an infection with SARS-CoV-2 by vaccination seems to be the best option to 
combat the global pandemic. By end of February 2021, more than 170 vaccines 
are tested in pre-clinical trials with more than 65 vaccines in clinical trials (WHO 
2021b). New and well-established platforms are used for the development of 
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vaccines against SARS-CoV-2 (Figure 5): (i) whole virus vaccines (attenuated 
or inactivated), (ii) replicating and non-replicating viral vectors, (iii) virus-like 
particles, (iv) DNA or RNA-based vaccines, (v) synthetic vaccines (synthetic 
peptides or protein subunits), and (vi) recombinant viral or bacterial vector 
vaccines. Most vaccines tested in clinical trials are protein subunit vaccines 
(32%) followed by non-replicating viral vector vaccines (16%) (LOCHT 2020; 
WHO 2021b). At the end of January 2021, two messenger RNA-based (mRNA) 
vaccines and one replication-deficient adenovirus vaccine are authorized and 
recommended for prevention of COVID-19 in Europe (CDC 2021a; WHO 
2021a). 
 
 
Figure 5: Approaches to vaccine development against SARS-CoV-2. Different platforms are used in 
the development of a vaccine. The brackets indicate the percentage of each platform tested in clinical 
trials. Protein subunit vaccines (32%) and non-replicating viral vector vaccines (16%) are most frequently 
represented in clinical trials (WHO 2021b). Created with BioRender.com 
 
The first one, named BNT162b2, is manufactures by Pfizer, Inc., and BioNTech. 
Clinical trials showed an efficacy of 95.0% to prevent a SARS-CoV-2 infection. 
The route of application is intramuscular in the upper arm using two shots with 
an interval of 21 days. The vaccine is recommended for individuals older than 
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16 years and the most common side effects include local pain or redness at the 
puncture site and systemic reactions such as fever, fatigue or headache (CDC 
2021c; POLACK et al. 2020; WALSH et al. 2020). 
 
The second one, named mRNA-1273, is manufactured by ModernaTX, Inc. 
Clinical trials showed an efficacy of 94.1% to prevent a SARS-CoV-2 infection. 
The route of application is intramuscular in the upper arm using two shots with 
an interval of 28 days. The vaccine is recommended for individuals older than 
18 years and the most common side effects include local pain or redness at the 
puncture site and systemic reactions such as fever, tiredness or headache 
(ANDERSON et al. 2020; BADEN et al. 2020; CDC 2021b).  
 
The third one, named AZD1222 or ChAdOx1-S (recombinant), is manufactured 
by the University of Oxford/AstraZeneca. The route of application is 
intramuscular in the upper arm using two shots with an interval of 28 to 84 days. 
The vaccine is recommended for individuals older than 18 years. However, due 
to a lack of clinical data, the vaccine efficacy in individuals >65 years is 
uncertain. The most common side effects following vaccination include local 
pain at the puncture site and systemic reactions such as headache, fatigue, 
myalgia and nausea (EMA 2021; WHO 2021d).  
 
The vaccines manufactured by Pfizer, Inc., BioNTech and ModernaTX, Inc.  use 
a mRNA encoding a pre-fusion stabilized version of the full-length SARS-CoV-
2 spike protein, which is delivered and translated in the cytoplasm of the host 
cell. In the last couple of years, mRNA became an encouraging alternative to 
other vaccine platforms, due to their safety, good immune response (high 
neutralizing and binding antibody titers, strong CD4+ and CD8+ T cell response) 
and the quick and low-cost manufacturing (CHUNG et al. 2020; PARDI et al. 
2018; POLACK et al. 2020). Nevertheless, there is still need for improvement 
because of instability and inefficient delivery in vivo (KARIKÓ et al. 2008; 
KAUFFMAN et al. 2016). 
 
In contrast, AZD1222 is based on a replication-deficient simian adenovirus 
expressing the codon-optimized full-length SARS-CoV-2 spike protein 
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intracellularly upon infection of the host cells (GILBERT and WARIMWE 2017; 
van DOREMALEN et al. 2020). The platform is well established and has been 
used to generate vaccines against several infectious pathogens including Ebola 
virus, Lassa virus and MERS-CoV (GILBERT and WARIMWE 2017). Preclinical 
and clinical studies with the new manufactured vaccine AZD1222 revealed a 
robust humoral and cell-mediated immune response (FOLEGATTI et al. 2020; 
GRAHAM et al. 2020; van DOREMALEN et al. 2020).  
2. Modified Vaccinia virus Ankara (MVA) as a viral 
vaccine  
2.1. History of MVA 
The Modified Vaccinia virus Ankara (MVA) was developed by passaging the 
virus on chicken embryonic fibroblasts (CEF) to create a safer vaccine against 
smallpox. The ancestor virus of MVA is Vaccinia virus strain (VACV) Ankara, 
cultured and amplified in Turkey as a vaccine against smallpox. VACV has been 
used as a vaccine for more than 200 years, but unfortunately, its application 
has been associated with rare but severe side effects. These side effects range 
from localized reactions to even death, mainly caused by post vaccinal 
encephalitis (MAYR 2003). In the early 1950s, VACV was distributed to Munich, 
where the virus was cultivated on chorioallantois membranes (CAM) of 
embryonated chicken eggs, renaming the virus as Chorioallantois Vaccinia 
virus Ankara (CVA) (HERRLICH and MAYR 1954). During the smallpox 
eradication campaign, CVA was amplified to obtain a safer vaccine against 
smallpox (1954/55). In parallel, the University of Munich was working on the 
genetic stability of CVA when cultivated on different tissue cultures and in 1968, 
after the 516th passage on chicken embryonic fibroblasts, CVA was renamed 
as Modified Vaccinia virus Ankara. MVA was distributed to the Bavarian State 
Institute for Vaccines for further testing and to confirm suitability as a vaccine 
against smallpox (STICKL and HOCHSTEIN-MINTZEL 1971). First attempts to 
vaccinate people with a MVA vaccine preparation showed no severe side 
effects (STICKL 1974). In 1977, MVA was authorized as primary pre-vaccine in 
Germany, and until 1980, more than 120,000 humans were vaccinated with 
MVA with no severe adverse events even when administered to patients at high 
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risk such as elderly or individuals with allergies and skin affections (MAHNEL 
and MAYR 1994; STICKL 1974). With the eradication of smallpox in 1977, 
further vaccination studies with the MVA vaccine stopped (VOLZ and SUTTER 
2016). Nevertheless, investigation on MVA continued and several years later, a 
restriction mapping of clonal isolate F6, derived from the 572nd passage on CEF 
cells, was performed, showing alterations compared to ancestor strain CVA 
(MEYER et al. 1991). Several mutations and large deletions were found, which 
affect genes involved in virus-host interactions. In total, around 30 kb of genetic 
information was lost, leading to a genome size of MVA of ~178 kb (ANTOINE 
et al. 1998; VOLZ and SUTTER 2016).  
2.2. Taxonomy and viral life cycle 
MVA belongs to the family poxviridae, subfamily chordopoxvirinae, and genus 
orthopoxvirus. Other members of genus orthopoxvirus include Variola virus 
(smallpox), monkeypox virus, cowpox virus and camelpox virus (GUBSER et al. 
2004) (Figure 6). 
 
 
Figure 6: Classification of Modified Vaccinia virus Ankara (MVA). MVA belongs to the family Poxvirus, 
subfamily Chordopoxvirinae, genus Orthopoxvirus, species Vaccinia virus. Modified from (GUBSER et al. 
2004). 
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Poxviruses are large and complex viruses (Figure 7). The envelope of 
extracellular virions (EV) contains two layers, an outer lipid membrane with 
short surface tubules visible upon electron microscope analysis and an inner 
lipid membrane. Inside is the core component of the virus particle with two 
lateral bodies that are important to deliver viral effector proteins into the host 
cell cytosol upon cell entry (BIDGOOD 2019; LALIBERTE et al. 2011). The core 
structure is formed by the core wall, which has a thick outer layer of structural 
proteins and a thin inner protein layer. The double-stranded DNA genome is 
tightly-packed as a nucleoprotein complex with the core structure. Of note, the 
nucleoprotein complex contains important viral enzymes that are also packaged 
within the virion (WESTWOOD et al. 1964). 
 
 
Figure 7: Schematic structure of a Modified Vaccinia virus Ankara (MVA) particle. MVA displays an 
envelope consisting of an outer lipid membrane (with surface tubules) and an inner lipid membrane. The 
inner part of the virion comprises a core structure with two lateral bodies. The core is surrounded by duplex 
protein layers and contains the DNA complex with viral enzymes in the inner part (WESTWOOD et al. 
1964). Created with BioRender.com 
 
Infectious viral particles are brick-shaped with a core structure containing the 
linear 178 kb duplex DNA. Several enzymes, including the DNA-dependent 
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RNA polymerase, capping and methylating enzymes are found within the virus 
core, enabling the virus to synthesize progeny mRNA after cell entry (Figure 
8). Once the mature virion (MV, not shown in the graph) or extracellular virion 
(EV) attach to and enter the host cell, viral DNA is uncoated and early genes 
are transcribed. These early genes encode proteins involved in replication of 
viral genome and transcription of intermediate genes. Afterwards, the viral 
progeny DNA is used as a template to translate intermediate and late genes. 
The three classes of genes (early, intermediate, and late) have promoters 
containing distinctive sequence elements (BALDICK et al. 1992; MOSS 1996), 
which are recognized by viral proteins. This allows for a sequential activation of 
genes during the life cycle of MVA. After translation of the late structural 
proteins, the virion is assembled, transported to the periphery (CUDMORE et 
al. 1995; STOKES 1976), budded through the plasma membrane and released 
from the host cell (PAYNE 1980).  
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Figure 8: Viral life cycle of poxviruses. Extracellular virions (EV) bind to host cells by the interaction of 
virion proteins with glycosaminoglycans (GAGs) on the surface of the cell. The complete replication cycle 
of poxviruses occurs in the cytoplasm of infected cells and is characterized by three steps of mRNA and 
protein synthesis (early, intermediate and late) following assembly and morphogenesis of infectious 
particles. The initial intracellular mature virus (IMV) is transported to the Golgi-apparatus and wrapped 
with Golgi-derived membranes, renaming IMV as intracellular enveloped virus (IEV). IEV is transported to 
the periphery and released by the host cell. Modified from (McFADDEN 2005; SUTTER 2020). Created 
with BioRender.com 
2.3. Virus-host interaction 
Wild type VACV has a subset of viral genes (“host range” genes) encoding 
regulatory proteins that are important to control intracellular host defense 
mechanisms. Most of these proteins are expressed at the early stage of 
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infection, allowing VACV and other poxviruses to inhibit the host cell innate 
immune response (SMITH 1993). MVA lost several of these immunomodulatory 
genes during the attenuation process on CEF cells (ANTOINE et al. 1998; 
CARROLL and MOSS 1997), which might explain the highly immunogenic 
property despite its restricted replication capacity in mammalian cells (GÓMEZ 
et al. 2011). However, MVA induces a cascade-like gene expression upon 
infection of non-permissive cells, but the assembly of virions is blocked at the 
late stage of the viral replication cycle (SUTTER and MOSS 1992). Interestingly, 
the amount of early and late viral proteins is comparable to those produced in 
permissive cells (SANCHO et al. 2002). Although, MVA cannot fulfill its 
complete viral life cycle, the induction of an efficient immune response against 
viral or bacterial antigens is not affected (SUTTER et al. 1994a).  
 
Poxviruses have developed several strategies to hamper the host cell immune 
response, including the inhibition of interferon pathways, the apoptotic response 
or production of cytokines and chemokines (SEET et al. 2003). In regard of IFN 
signaling pathways, VACV expresses a large panel of proteins blocking the 
induction of several transcription factors, such as NF-κB, IRF-3 or IRF-7 (SMITH 
et al. 2001). The pathways are activated by double-stranded (ds) RNAs and 
include the interferon-inducible protein kinase DAI (dsRNA-activated inhibitor of 
translation) and the 2`-5`oligoadenolyate synthase (MANCHE et al. 1992). The 
latter activates an endo-RNase preventing protein synthesis by the cleavage of 
mRNA. Upon activation, the DAI kinase phosphorylates the alpha subunit of the 
eukaryotic translation initiation factor 2 (eIF2α), causing an inhibition of protein 
synthesis at early stage. Viral proteins, such as C7, K1, K3 and E3 are able to 
block virus-induced phosphorylation of eIF2α. Furthermore, E3 inhibits 
phosphorylation of the two transcription factors IRF-3 and IRF-7 (BACKES et 
al. 2010; CHANG et al. 1992; SMITH et al. 2001), blocking type-I interferon 
release in VACV. MVA lacks several of these proteins (e.g., A52, B14, K1, C4, 
M2, N1), resulting in an upregulation of interferon pathways upon infection of 
host cells. A key feature of MVA as a viral vector vaccine is the strong induction 
of cytotoxic T cell responses by the activation of type-I IFNs in human antigen-
presenting cells such as dendritic cells (BÜTTNER et al. 1995; DRILLIEN et al. 
2004). Gene profiling analysis of MVA infected dendritic cells revealed elevated 
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mRNA levels of IL-12, IFN-α/β, IRF-7 and proteins activating the type-I IFN 
production (MDA5, RIG) (GUERRA et al. 2007). Another immune evasion 
mechanism of VACV connected to the interferon pathway is the expression of 
soluble receptors for TNF, IFN-γ, and IFN-α/β. These secreted receptors allow 
evading and inhibiting of the host immune system, and their high prevalence in 
the serum is associated with high virulence (HU et al. 1994; MOSSMAN et al. 
1995; SMITH et al. 1997; SPRIGGS et al. 1992). MVA lacks genes to encode 
those receptors and thus, induces an innate immune response. Furthermore, 
MVA infection induces the production of chemokines (e.g., CCL2) and activation 
of the complement system, causing an increased migration of leucocytes to the 
source of infection (LEHMANN et al. 2009). 
 
Besides, apoptosis of infected cells is blocked by certain VACV proteins. 
Programmed cell death is mediated by caspases and B-cell lymphoma (Bcl)-2 
and Bcl-2-like proteins at the mitochondrion. Once apoptosis is activated, the 
pro-apoptotic proteins Bid, Bim and PUMA activate Bax/Bak or NOXA which 
assemble pores in the mitochondrial membrane (CHIPUK et al. 2010; REN et 
al. 2010). The pores allow the release of cytochrome c from the mitochondrial 
intermembrane space into the cytosol, causing the assemble of the apoptosome 
complex. Thereby, caspase-3 and caspase-7 are activated and the subsequent 
cascade leads to the death of infected cells (DANIAL and KORSMEYER 2004). 
Anti-apoptotic proteins such as Bcl-2, Bcl-w or Bfl-1 interfere with pro-apoptotic 
proteins to block Bax/Bak activation. The VACV E3 protein binds to the pro-
apoptotic NOXA protein, inhibiting apoptosis in infected cells (DAVIES et al. 
1992; VEYER et al. 2017).  
2.4. MVA as a viral vector vaccine  
Due to the replication deficiency of MVA in most cells of mammalian origin and 
the possibility to use the virus for high-level expression of various recombinant 
proteins, MVA is a promising tool to create viral vector vaccines. Moreover, 
recombinant Vaccinia viruses induce high levels of cytotoxic CD8+ T cells in 
immunized animals and humans. The intracellular expression of a target 
antigen allows for processing and presentation to major histocompatibility 
complex (MHC) class I molecules for recognition by T cells (TOWNSEND et al. 
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1988). 
  
The target genes (viral or bacterial antigens) can easily be inserted into one of 
the deletions sites of MVA by homologous recombination. By cloning the genes 
into these sites, changes in genotype and phenotype can be avoided (VOLZ 
and SUTTER 2016). The time-point and amount of expressed antigen is 
controlled by the choice of an early, intermediate or late promoter. The highest 
amount of expressed antigen was observed with late or early/late promoters 
(MACKETT et al. 1984). To generate a recombinant MVA, some general rules 
need to be considered. A transfer plasmid is required, containing an expression 
cassette (poxvirus promoter and a multiple cloning site with restriction sites to 
insert the foreign antigen), which is flanked by poxvirus DNA sequences to 
direct recombination into the preferred locus (EARL et al. 1990; MACKETT et 
al. 1984; STAIB et al. 2004). The DNA sequence TTTTTNT functions as a stop 
signal for viral early gene transcription and foreign antigens should be screened 
for this thymidine rich regions. Furthermore, G/C-runs could lead to a frameshift 
in the MVA genome during DNA replication (WYATT et al. 2009). If the target 
antigen contains these runs of thymidines or G/Cs, the codon usage should be 
changed (EARL et al. 1990). The efficiency of homologous recombination is 
around 0.1% and screening for positive plaques can be performed either by 
DNA hybridization, expression of target antigen (PICCINI et al. 1987), co-
integration of antibiotic selection marker (FRANKE et al. 1985) or co-expression 
of marker genes (WONG et al. 2011). The very first proteins that were 
expressed by recombinant MVAs were the E. coli enzymes guanine-
phosphoribosyl-transferase (GPT) and β-galactosidase using gene sequences, 
which were inserted into deletion site III (SUTTER and MOSS 1992).  
2.5. Vaccinia virus vaccines in veterinary and human 
vaccine trials 
Various recombinant Vaccinia viruses were used in animals against viruses of 
veterinary importance, such as vesicular stomatitis virus (VSV) (MACKETT et 
al. 1985), Rinderpest virus (RPV) (YILMA et al. 1988) or rabies virus (RABV) 
(WIKTOR et al. 1984). Raccoonpox virus vectors were used to prevent RABV 
infections in raccoons (ESPOSITO et al. 1988), capripox virus vectors were 
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used to protect cattle against RPV (ROMERO et al. 1994), fowlpox vectors were 
used to protect chicken against influenza virus (WEBSTER et al. 1991) and 
canarypox virus were used to protect dogs against canine distemper virus 
(CDV) (TAYLOR et al. 1991). 
 
Besides, several Vaccinia virus-based vaccines were used in human vaccine 
trials. In the beginning of the 1990s a randomized phase I clinical trial was 
performed in the USA to test safety and immunogenicity of a recombinant 
Vaccinia virus expressing the envelope protein from human immunodeficiency 
virus 1 (HIV-1). No severe side effects were observed and a prime-boost 
vaccination induced humoral and cell-mediated immune responses (COONEY 
et al. 1991; GRAHAM et al. 1992). A few years later, a recombinant Vaccinia 
virus expressing the membrane protein from Epstein-Barr virus (EBV) was 
administered in China to infants and young children, showing immunogenic 
properties. Over a period of 16 months, natural infections with EBV could be 
delayed or even prevented (GU et al. 1995).   
 
The first recombinant MVA-based candidate vaccine expressing two proteins, 
hemagglutinin (HA) and nucleoprotein of influenza A virus, was tested in mice 
for immunogenicity. High levels of antibodies and cytotoxic T cells could be 
found. Moreover, vaccinated mice could be protected in a challenge model 
following infection with influenza A virus (HESSEL et al. 2014; SUTTER et al. 
1994b). Over the last decades, several MVA-based vaccines were tested in 
various preclinical and clinical trials, including vaccines against Ebola virus 
(ANYWAINE et al. 2019), HIV (MUNSERI et al. 2015) and Mycobacterium 
tuberculosis (MANJALY THOMAS et al. 2019). Recently, an MVA-based 
vaccine against MERS-CoV, closely related to new SARS-CoV-2, was tested in 
a phase I clinical trial, showing strong humoral and cell-mediated immune 
response (KOCH et al. 2020; SONG et al. 2013; VOLZ et al. 2015).  
3. Viral infection and host immune response 
The immune system can be divided into two main parts that act in a synergetic 
way: adaptive and innate immunity. The latter is the first immunological barrier 
against pathogens, showing a rapid (within minutes or hours) and non-specific 
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immune response that has no immunological memory (MURPHY et al. 2014; 
WARRINGTON et al. 2011). The main function is to recruit certain immune cells 
to sites of infection and to produce cytokines causing an inflammation. 
Production of cytokines triggers the release of antibodies and specific 
glycoproteins resulting in an activation of the complement system (LING and 
MURALI 2019). The innate immunity is also responsible for clearance of dead 
cells and promotes removal of foreign substances in various organs, blood and 
lymph. Furthermore, the innate immunity activates the adaptive immunity by 
antigen presentation through phagocytes such as macrophages, neutrophils or 
dendritic cells (TURVEY and BROIDE 2009; WARRINGTON et al. 2011). 
 
In contrast, the adaptive immunity acts in an antigen-dependent and antigen-
specific manner and has the capacity to develop memory, allowing a rapid 
response after re-infection with a given pathogen (MURPHY et al. 2014; 
WARRINGTON et al. 2011). This branch of the immune system is activated 
when the innate immunity is not able to eliminate a certain pathogen and the 
infection is established. The main tasks are the recognition of foreign antigens, 
the activation of effector pathways and the development of an immunologic 
memory. The adaptive immunity can be further classified into cell-mediated (T 
cell) response and antibody-mediated (B cell) response (BONILLA and 
OETTGEN 2010).  
 
T cells originate from hematopoietic stem cells in the bone marrow and mature 
in the thymus, expressing one unique antigen-binding receptor, known as T cell 
receptor (TCR). TCRs interact with antigen-presenting cells (APCs), such as 
macrophages or dendritic cells, to recognize a certain antigen. APCs encode 
cell-surface proteins, which are named major histocompatibility complex 
(MHC). MHC are further divided into class I, which is broadly distributed on all 
nucleated cells, and class II, which is found only on specific immune cells, such 
as macrophages and dendritic cells. Class I MHC molecules present 
intracellular peptides whereas class II MHC molecules display extracellular 
peptides. Those peptides are fragments of antigens, presented by cells after 
contact or infection with a pathogen (BONILLA and OETTGEN 2010; MURPHY 
et al. 2014). T cells bind with their TCRs to the fragmented antigens on MHC 
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molecules and secret cytokines which further active the immune cascade, 
causing a differentiation of T cells into cytotoxic T cells (CD8+ T cells) or T-
helper (Th) cells (CD4+ T cells) (WARRINGTON et al. 2011). CD8+ T cells are 
responsible for destruction of infected cells and are activated by interaction of 
class I MHC bound peptides. Clonal expansion of CD8+ T cells leads to the 
maturation of effector cells which secrete perforin, granzyme and granulysin, 
thereby inducing lysis and apoptosis of infected cells. Once the infection is 
cleared, most effector cells die, but a small portion become memory cells which 
differentiate quickly into effector cells after re-infection with a known antigen 
(BONILLA and OETTGEN 2010; MURPHY et al. 2014; WARRINGTON et al. 
2011).  
 
The major role of CD4+ T cells is to shape the adaptive immune response by 
influencing the function of other immune cells. They are activated by the 
interplay of their TCRs with class II MHC bound molecules, releasing cytokines 
which active other immune cells. CD4+ T cells are divided into two types: Th1 
and Th2. Once Th1 cells are activated, IFN-γ and other cytokines are released, 
inducing B cells to produce (neutralizing) antibodies. Th2 activation causes the 
release of cytokines (e.g., IL-4 and IL-13) which activate IgE-antibody producing 
B cells and eosinophils. Similar to cytotoxic CD8+ T cells, most Th cells die after 
clearance of the infection, with a small amount remaining as memory cells 
(BONILLA and OETTGEN 2010; MURPHY et al. 2014; NICHOLSON 2016).  
 
B cells derive from hematopoietic stem cells in the bone marrow, expressing 
one unique antigen receptor after maturation. In contrast to T cells, B cells need 
no APCs and recognize foreign antigens directly. The main task of B cells is the 
production of specific antibodies against pathogens (MURPHY et al. 2014). 
Once B cells are activated by recognizing foreign antigens, they differentiate 
into antibody-secreting plasma cells or memory cells. The latter are long-living, 
continually expressing antigen-binding receptors and respond quickly upon re-
infection with known antigens. Plasma cells are short-living, express no antigen-
binding receptors and die once the infection is cleared (BONILLA and 
OETTGEN 2010; WARRINGTON et al. 2011). Secreted antibodies are 
classified into five different types: immunoglobulin (Ig) A, IgG, IgE, IgM and IgD 
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(MURPHY et al. 2014; SCHROEDER and CAVACINI 2010). Immunoglobulins 
consist of two polypeptide chains, a heavy and a light chain. Each Ig molecule 
has two heavy and two light chains which are connected by disulfide bonds. 
The structure of the B cell receptor is identical to its corresponding antibody, 
beside a small part at the C- terminus of the heavy chain. The B cell receptor 
has a hydrophobic part to bind to the membrane of the B cell, whereas the 
antibody has a hydrophilic sequence allowing secretion (MURPHY et al. 2014). 
The most important antibodies in terms of clearance of pathogens are IgA, IgG 
and IgM. The latter is expressed during early stage of infection and opsonizes 
the pathogen for destruction. IgA is responsible for mucosal response, either by 
neutralizing viral or bacterial antigens or inhibiting the binding to the mucosal 
surface. The main circulating immunoglobulin, IgG, is expressed at later stage 
of infection and opsonize the antigens for destruction and neutralizes the virus 
(MURPHY et al. 2014; SCHROEDER and CAVACINI 2010).
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IV. MATERIAL AND METHODS 
1. Materials 
1.1. Organism 
1.1.1. Bacterial strains 
NEB 10-beta bacteria (New England Biolabs, Frankfurt, Germany) were used 
for heat-shock transformation and amplification of plasmid DNA. 
1.1.2. Cell lines 
Table 1: Overview of cell lines 
Cell line Detailed information Experiment 
A549  
 
adenocarcinomic, alveolar basal 
epithelial cells (human) 
protein expression, growth 
kinetics 
CEF chicken embryonic fibroblasts virus amplification, protein 
expression 
DF-1 
 
chicken embryonic fibroblasts  virus amplification, plaque 
passage, growth kinetics, 
protein expression 
HaCat epidermal keratinocyte cells (human) protein expression, growth 
kinetics 
HeLa  
 
cervical cancer cells (human) protein expression, growth 
kinetics 
Vero E6  kidney epithelial cells (African green 
monkey) 
protein expression, virus 
neutralization assay (VNT) 
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1.2. Antibodies 
1.2.1. Primary antibodies 
Table 2: Primary antibodies used for western blot analysis (WB), immunofluorescence assay (IFA) 
and intracellular cytokine staining (ICS) 
Antigen Supplier Species WB IFA ICS 
CD3 phycoerithrin 
(PE)-Cy7 
Biolegend, 
London, United 
Kingdom 
mouse - - 1:100 
CD4  
Brilliant Violet  
Biolegend, 
London, United 
Kingdom 
mouse - - 1:600 
CD8α Alexa Fluor 
488 
Biolegend, 
London, United 
Kingdom 
mouse - - 1:300 
CD16/CD32 Biolegend, 
London, United 
Kingdom 
mouse - - 1:500 
HA-tag  Thermo Fisher 
Scientific, 
Planegg, 
Germany 
mouse 1:7,000 1:1,000 - 
IFN-γ Biolegend, 
London, United 
Kingdom 
mouse - - 1:200 
spike protein  Biozol GmbH, 
Eching, 
Germany 
mouse 1:1,000 1:200 - 
TNF-α Biolegend, 
London, United 
Kingdom 
mouse - - 1:200 
Vaccinia virus A27L 
protein 
oriGene, 
Herford, 
Germany 
rabbit - 1:2,000 - 
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1.2.2. Secondary antibodies 
Table 3: Secondary antibodies used for western blot analysis (WB) and immunofluorescence assay 
(IFA) 
Name Supplier Origin WB IFA 
Anti-mouse IgG HRP Agilent Technologies, 
Waldbronn, 
Germany 
goat 1:5,000 1:1000 
Anti-rabbit IgG HRP Cell Signaling, Frankfurt am 
Main, Germany 
goat 1:5,000 - 
Anti-rabbit IgG 
peroxidase 
conjugated 
Jackson Immuno Research, 
Suffolk, United Kingdom 
goat - 1:5,000 
 
1.3. Oligonucleotides 
Table 4: Oligonucleotides used for control PCR 
Name Sequence (5´ 3´) PCR 
MVA-Del 1 for CTTCGCAGCATAAGTAGTATGTC Deletion I 
MVA-Del 1 rev CATTACCGCTTCATTCTTATATTC Deletion I 
MVA-Del 2 for GGGTAAAATTGTAGCATCATATACC Deletion II  
MVA-Del 2 rev AAAGCTTTCTCTCTAGCAAAGATG Deletion II 
MVA-Del 3 for GATGAGTGTAGATGCTGTTATTTTG Deletion III  
MVA-Del 3 rev GCAGCTAAAAGAATAATGGAATTG Deletion III 
MVA-Del 4 for AGATAGTGGAAGATACAACTGTTACG Deletion IV 
MVA-Del 4 rev TCTCTATCGGTGAGATACAAATACC Deletion IV 
MVA-Del 5 for CGTGTATAACATCTTTGATAGAATCAG Deletion V  
MVA-Del 5 rev AACATAGCGGTGTACTAATTGATTT Deletion V 
MVA-Del 6 for CTACAGGTTCTGGTTCTTTATCCT Deletion VI  
MVA-Del 6 rev CACGGTCAATTAACTATAGCTCTG Deletion VI 
III-3´ GTACCGGCATCTCTAGCAGT Deletion III  
III-5´ TGACGAGGTTCCGAGTTCC Deletion III 
SARS-CoV-2 for 1 CCAGAACTCAATTACCCCCTGC Insert 
SARS-CoV-2 rev 1 CATTACAAGGTGTGCTACCGGC Insert  
SARS-CoV-2 for 2 ACAAATCGCTCCAGGGCAAAC Insert  
SARS-CoV-2 rev 2 GCCCCTATTAAACAGCCTGCAC Insert  
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SARS-CoV-2 for 3 TGGCAGAGACATTGCTGACAC Insert  
SARS-CoV-2 rev 3 GCACCAAAGGTCCAACCAGAAG Insert  
SARS-CoV-2 for 4 TCAGACTAATTCTCCTCGGCGG Insert  
SARS-CoV-2 rev 4 CAGCCCTTGAGACAACTACAGC Insert  
C7L for CATGGACTCATAATCTCTATAC C7L  
C7L rev ATGGGTATACAGCACGAATTC C7L  
 
1.4. Plasmids 
Table 5: Expression and shuttle plasmids  
Plasmid Supplier Experiment 
pUC57-SARS-CoV-2-S Genewiz, Leipzig, 
Germany 
cloning 
pIIIH5red-SARS-CoV-2-S Alina Tscherne, LMU cloning 
pIIIH5red Gerd Sutter, LMU cloning 
 
1.5. Peptides 
Table 6: Selected peptides with predicted class I MHC (H2d) and class II MHC (IAd and IEd) 
restriction 
Peptide ID Peptide Length Start End Pool # 
S1 GYLQPRTFL 9 268 276 4 
S2 AYSNNSIAI 9 706 714 10 
S3 IYQAGSTPCNGV 12 472 483 5 
S4 FTISVTTEI 9 718 726 10 
S5 IYQTSNFRV 9 312 320 10 
S6 IYQAGSTPC 9 472 480 5 
S7 QYIKWPWYI 9 1208 1216 6 
S8 CYGVSPTKL 9 379 387 11 
S9 PPIKDFGGFNF 11 792 802 11 
S10 VGYQPYRVVVL 11 503 513 7 
S11 KYNENGTIT 9 278 286 4 
S12 GYQPYRVVV 9 504 512 7 
S13 QYGSFCTQL 9 755 763 8 
S14 SYQTQTNSP 9 673 681 8 
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S15 YQPYRVVVL 9 505 513 7 
S16 WPWYIWLGF 9 1212 1220 6 
S17 VYAWNRKRI 9 350 358 9 
S18 CGPKKSTNL 9 525 533 9 
S19 KYFKNHTSP 9 1154 1162 9 
S20 TRFASVYAWNRKRIS 15 345 359 1 
S21 RFASVYAWNRKRISN 15 346 360 1 
S22 FASVYAWNRKRISNC 15 347 361 1 
S23 INITRFQTLLALHRS 15 233 247 2 
S24 NYLYRLFRKSNLKPF 15 450 464 2 
S25 LIRAAEIRASANLAA 15 1012 1026 3 
S26 NYNYLYRLFRKSNLK 15 448 462 2 
S27 ASVYAWNRKRISNCV 15 348 362 1 
S28 IRAAEIRASANLAAT 15 1013 1027 3 
S29 GNYNYLYRLFRKSNL 15 447 461 2 
S30 AAEIRASANLAATKM 15 1015 1029 3 
S31 GGNYNYLYRLFRKSN 15 446 460 2 
S32 RAAEIRASANLAATK 15 1014 1028 3 
S33 ATRFASVYAWNRKRI 15 344 358 1 
S34 NATRFASVYAWNRKR 15 343 357 1 
F2(G) SPGAAGYDL 9 26 34 - 
 
2. Methods 
2.1. Cell culture 
2.1.1. Passaging, freezing and thawing of cells 
Eucaryotic cells were washed once with 1x DPBS, trypsinized with 1x TrypLE™ 
Select Enzym for 5-10 min at 37 °C. 7-9 ml of cell culture medium were added 
to stop the enzymatic reaction. One part of the cell suspension was distributed 
to new flasks, filled up with cell culture medium and cells were cultured at 37 °C 
with 5% CO2. DF-1 cells were kept in VP-SFM medium supplemented with 2% 
L-glutamine and 2% heat-inactivated FBS. CEF cells were isolated from 10 to 
11-day old chicken embryos and were maintained in VP-SFM medium, 10% 
FBS and 1% L-glutamine. Vero E6 cells were cultured in DMEM with 10% FBS 
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and 1% MEM non-essential amino acid solution. Human A549 cells were 
maintained in DMEM (+ 4500 mg/l glucose) containing 10% FBS. Human HeLa 
cells were maintained in MEM, 7% FBS and 1% MEM non-essential amino acid 
solution. Human HaCat cells were maintained in DMEM, 1% MEM non-
essential amino acid solution, 10% FBS and 1% HEPES solution. 
 
To freeze cells, the protocol for passaging cells was followed until the enzymatic 
reaction of trypsin was stopped. The cell suspension was centrifuged and the 
pellet was resuspended in freezing medium (45% FBS, 45% cell culture 
medium, 10% DMSO). The cells were immediately distributed to cryo tubes and 
frozen at -80 °C. For long term storage, cells were transferred to liquid nitrogen. 
To thaw the cells, cryo tubes were taken from liquid nitrogen or -80 °C, carefully 
thawed in a water bath (37 °C) and immediately filled up with medium to dilute 
the toxic DMSO. Cells were distributed to cell culture flasks and cultured at 37 
°C with 5% CO2. Medium was changed the day after to remove dead cells. 
2.1.2. Generation and purification of recombinant viruses  
To obtain the recombinant MVA vector virus a well-established protocol was 
used as described previously (ALTENBURG et al. 2014; KOCH et al. 2020; 
SONG et al. 2013). Briefly, clonal isolate MVA-F6sfMR was grown on CEF cells 
under serum-free conditions and was used as a non-recombinant backbone 
virus to insert the SARS-CoV-2 spike gene sequence. 6-well tissue culture 
plates with 90-95% confluent DF-1 or CEF cells were infected with non-
recombinant MVA-F6sfMR at a multiplicity of infection (MOI) of 0.05 and 
transfected with 1 µg DNA of expression plasmid pIIIH5red-SARS-CoV-2-S 
using X-tremeGENE HP DNA Transfection Reagent according to the manual. 
Cells were cultured for 48 h at 37 °C and collected afterwards. Recombinant 
MVA viruses were clonally isolated by serial rounds of plaque purification on 
DF-1 or CEF cell monolayers screening for transient co-expression of the 
marker protein mCherry. To obtain large scale virus preparations, recombinant 
MVA-SARS-CoV-2-S was amplified on DF-1 cells grown in T175 tissue culture 
flasks. The virus was purified via ultracentrifugation through 36% sucrose and 
reconstituted in TBS (pH =7.4). For long term storage, recombinant viruses 
were frozen at -80 °C.  
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2.1.3. Determination of plaque-forming units (PFU) 
Recombinant MVA was diluted in 10-fold dilution steps (range 1:10*4 to 1:10*9) 
and used to infect 6-well tissue plates with 90-95% confluent CEF cells. Each 
dilution was prepared in triplicates. Cells were incubated for 48 h and 
afterwards, fixed with ice-cold methanol: acetone (1:1) for 5 min. Plates were 
blocked with PBS (+ 3% FBS) for 1 h at RT or 4 °C o/n. Plates were washed 3x 
with PBS. Primary antibody (anti-Vaccinia virus or anti-HA) was diluted in PBS 
(+ 3% FBS) and plates were incubated for 1 h at RT. Subsequently, plates were 
washed 3x with PBS. Secondary antibody (goat anti-mouse HRP) was diluted 
in PBS (+ 3% FBS) and plates were incubated for 1 h at RT. Afterwards, plates 
were washed 3x with PBS and TrueBlue™ Peroxidase Substrate was added to 
each well until color change could be observed. Plaque-forming units per ml 
(PFU/ml) were determined by counting the plaques.  
2.1.4. Growth kinetics on permissive and non-permissive cell 
lines 
DF-1, HeLa, HaCat and A549 cells were grown on 6-well tissue plates at a 
confluency of 90-95% and were infected with recombinant MVA at a MOI of 
0.05. After certain time points (0, 4, 8, 12, 24, 48 and 72 hpi), whole wells were 
collected and frozen at -20 °C. Three freeze and thaw cycles were performed 
before sonicating three times for 1 min. Afterwards, back titration on CEF cells 
was performed using the protocol descripted in chapter 2.1.3 Determination of 
plaque-forming units (PFU).  
2.1.5. Low MOI passage 
A monolayer of 90-95% confluent DF-1 cells was infected with recombinant 
MVA at a MOI of 0.05 and cultured for 48 h at 37 °C. Afterwards, the amplified 
virus was collected and used to re-infect confluent 6-well tissue plates with DF-
1 cells at a MOI of 0.05. This procedure was repeated four times, ending up 
with five rounds of low MOI passaging. Genetic stability of recombinant MVA-
SARS-CoV-2-S was further validated by PCR analysis and gene expression 
was monitored by SARS-CoV-2 spike protein specific immunostaining.  
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2.1.6. SARS-CoV-2 virus neutralization test (VNT) (performed at 
the Institute of Virology, Philipps University Marburg) 
Mice were immunized according to chapter 2.4.1 vaccination experiments and 
heat-inactivated serum samples were send to Prof. Dr. Stephan Becker`s lab, 
located at the Philipps University Marburg (Germany), to test the sera for their 
neutralization capacity using a protocol described previously (KREER et al. 
2020). Briefly, samples were serially diluted starting with a 1:16 dilution and 
incubated with 100 TCID50 SARS-CoV-2 (BavPat1/2020 isolate, European 
Virus Archive Global # 026V-03883) for 1 h at 37 °C. Serum/virus mixture was 
added to 96-well tissue culture plates with Vero E6 cells and cultured for four 
days. Neutralization capacity was determined as the absence of cytopathic 
effect compared to virus control. 
2.2. Biochemistry 
2.2.1. Generation of cell lysates 
6-well tissue plates or 24-well tissue plates with cells at a confluency of 90- 95% 
were infected with recombinant MVA at a MOI of 10 and were incubated for 0, 
2, 8, 12, 24 and 48 h at 37 °C. Non-infected cells and cells infected with wild-
type MVA were used as controls. To generate the lysates, cells were scraped 
from the plates and centrifuged for 1 min at 13,000 rpm. Supernatant was 
removed and the pellets were washed once with pre-chilled PBS. PBS was 
removed and pellets were reconstituted with lysis buffer (+ proteinase inhibitor). 
The cells were incubated for 30-60 min on ice and centrifuged for 15 min at 
13,000 rpm. The lysates were frozen at -80°C.  
2.2.2. SDS-PAGE and western blot analysis 
Cell lysates (description chapter 2.2.1 Generation of cell lysates) were thawed 
carefully on ice and mixed with 4x reducing agent containing β-
mercaptoethanol. The samples were boiled for 5 min at 95 °C and cooled down 
to RT. Subsequently, samples and a protein standard (Pageruler prestained 
protein ladder) were loaded on a pre-cast gel and proteins were separated by 
using 100 V for 2 h. The proteins were transferred on a nitrocellulose membrane 
using 100 V for 100 min. Afterwards, the membrane was blocked with blocking 
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buffer (1% BSA in PBST) for 1-2 h at RT. The first antibody (anti-HA) was diluted 
in blocking buffer and membrane was incubated for 1 h at RT before washing 
the membrane 3x with PBST for 10 min. The secondary antibody (goat anti-
mouse HRP) was diluted in blocking buffer and the membrane was incubated 
for 1 h at RT. After washing 3x with PBST, the membrane was incubated with 
SuperSignal West Dura Extended Duration Substrate for 1 min and proteins 
were detected by using the ChemiDocTMMP, Imaging System. 
2.2.3. Immunofluorescence 
Vero E6 cells were grown on cover slips in 6-well tissue culture plates. 90-95% 
confluent cells were infected at a MOI of 0.05 with recombinant MVA-SARS-
CoV-2-S and non-recombinant MVA. Non-infected cells served as a control. 
After incubation for 24 h at 37 °C, cells were fixed with 4% 
paraformaldehyde/PBS for 10 min on ice. Cells were washed with PBS, 
permeabilized with 0.1% Triton X-100/PBS and probed with an antibody against 
the HA-tag epitope. Non-permeabilized cells were probed with an antibody 
against the spike protein and fixed with 4% paraformaldehyde/PBS afterwards. 
A secondary goat anti-mouse antibody was used for visualization of S-specific 
staining by red fluorescence. DAPI (1 µg/ml) was used to stain the nuclei and 
cells were further analyzed by Keyence BZ-X700 microscope with a ×100 
objective. 
2.3. Molecular biology 
2.3.1. Heat-shock transformation 
Competent bacteria were carefully thawed on ice and pre-chilled plasmid DNA 
(100-500 ng) was added by slowly pipetting up and down. The tubes were 
incubated for 30 min on 4 °C and afterwards, bacteria were heat- shocked at 42 
°C for 30 sec.  LB-medium without antibiotics was added to the bacteria, which 
were then incubated for 1-3 h at 37 °C. Bacteria were plated on LB-agar plates 
containing antibiotics (50 µg/ml ampicillin or 50 µg/ml kanamycin) and incubated 
o/n at 37 °C. Colonies were selected and grown in LB-medium (+ antibiotics) 
for plasmid isolation. 
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2.3.2. Isolation of plasmid and viral DNA 
To obtain small amounts of plasmid DNA, the NucleoSpin Plasmid Mini kit for 
plasmid DNA was used according to the manual. Briefly, bacteria were 
centrifuged for 1 min at 13,000 rpm. Supernatant was discarded and the pellet 
was resuspended with pre-chilled resuspension buffer R1 (+ RNAse inhibitor). 
Lysis buffer A2 was added and tubes were incubated for 5 min at RT before 
adding neutralization buffer A3. Tubes were centrifuged for 10 min at 13,000 
rpm and the supernatant was loaded on columns. Afterwards, tubes were 
centrifuged for 1 min at 13,000 rpm and the flow through was discarded. Wash 
buffer AQ was added to the tubes and after centrifugation for 3 min at 13,000 
rpm, the DNA was eluted by adding elution buffer AE. 
 
To obtain larger amounts of plasmid DNA, the NucleoBond Xtra Midi kit was 
used according to the manual. Briefly, bacteria were centrifuged for 30 min at 
4,500 rpm and the pellet was resuspended in pre-chilled buffer RES (+ RNAse 
inhibitor). Lysis Buffer LYS was added and the tubes were incubated for 5 min 
at RT before adding buffer NEU. The supernatant was loaded on NucleoBond 
Xtra Column Filter and the flow through was discarded. Buffer WASH was 
added and afterwards, the DNA was collected by adding buffer ELU. To 
precipitate the DNA, isopropanol was used and the pellet was washed once 
with 96% ethanol. The pellet was dried and reconstituted with ddH2O.  
 
To obtain viral DNA, the NucleoSpin Blood Kit was used according to the 
manual. Briefly, infected cells were scraped from the tissue culture plates and 
centrifuged for 2 min at 2,000 rpm. Supernatant was discarded, the pellet was 
resuspended in buffer BQ1 (+ proteinase K) and incubated at 70 °C for 15 min. 
Afterwards, 96% ethanol was added and the liquid was loaded on columns. The 
tubes were centrifuged for 1 min at 13,000 rpm, the flow through was discarded 
and the columns were washed twice with wash buffer BQ2. To elute the DNA, 
pre-heated buffer BE was added to the columns and the tubes were centrifuged 
for 1 min at 13,000 rpm. The DNA was stored at -20 °C until further analysis. 
2.3.3. Digestion with restriction enzymes 
Plasmid DNA was digested with restriction enzymes for 90 min at 37 °C. 
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Restriction enzymes (NotI, PmeI, EcoRI) were obtained from New England 
Biolabs, Frankfurt, Germany. The following protocol was used to digest plasmid 
DNA: 
500-1000 ng plasmid DNA 
5 µl restriction buffer (10x) 
0.2 µl enzyme A 
0.2 µl enzyme B 
ad 50 µl ddH2O 
2.3.4. Polymerase chain reaction (PCR) 
PCR was used to amply specific regions of plasmid or viral DNA using the Taq 
DNA polymerase according to the manual. The oligonucleotide sequences are 
summarized in chapter 1.3 Oligonucleotides. The following protocol was used: 
 
 Final concentration 
0.2 µl polymerase (5 U/µl) 2.5 U/µl 
2.5 µl buffer (10x) 1x 
1 µl forward primer (10 µM)  0.5 µM 
1 µl reverse primer (10 µM) 0.5 µM 
0.75 µl MgCl2 (50 mM) 1.5 mM 
0.5 µl dNTP-Mix (2.5 mM) 0.05 mM each 
5 µl template 1-500 ng 
14.55 µl ddH2O - 
 
Table 7: Temperature profile for control PCR 
Step Temperature  Time 
Initial Denaturation 94 °C 5 min 
Denature 
 
Anneal 
Extend 
94 °C 45 sec 
Depending on primer Tm 
(55-70 °C) 
30 sec 
72 °C 90 sec/kb 
Final extension 72 °C 10 min 
Hold 4 °C indefinitely 
 
30x  
PCR  
cycle
s 
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2.3.5. Quantitative real-time reverse transcription PCR (qRT-
PCR) (performed at the Institute of Virology, Philipps 
University Marburg) 
Mice were immunized as described in chapter 2.4.1 Vaccination experiments. 
The immunized mice were shipped to Prof. Dr. Stephan Becker`s lab, located 
at the Philipps University Marburg (Germany), and challenged as descripted in 
chapter 2.4.2 Transduction of vaccinated mice and challenge infection with 
SARS-CoV-2. Tissue samples were excised from the left lung lobes and 
homogenized in DMEM. Isolation of RNA was achieved using the RNeasy Mini 
Kit according to the manual. Briefly, cells were lysed with buffer RLT, 
homogenized and afterwards, ethanol was added to the mixture. The liquid was 
loaded on columns and centrifuged for 1 min at 13,000 rpm. The columns were 
washed 3x with buffer RW1 and total RNA was eluted in RNAse-free water. 
Total RNA was reverse transcribed and quantified by RT-PCR (OneStep RT-
PCR Kit) using a protocol and primers as described before (CORMAN and 
DROSTEN 2020). Additionally, determination of mCherry mRNA was 
performed by RT-PCR for every tissue sample to confirm successful ACE2 
transduction. Quantification was performed by using a standard curve based on 
10-fold serial dilutions of control RNA (range: 10*2 to 10*5 copies).  
2.3.6. Gel electrophoresis 
Gel electrophoresis was performed to separate digested DNA or PCR products 
according to their sizes. Agarose (0.5-1.5%) was dissolved in 1x TAE buffer and 
boiled in a microwave. GelRed was added and the liquid gel was poured in a 
chamber. The digested DNA or PCR products were mixed with 5x DNA loading 
dye and loaded on the solid gel. To separate the DNA fragments, 100 V for 2 h 
were used. Subsequently, the DNA fragments were analyzed with UV light. 
2.4. Immunology 
2.4.1. Vaccination experiments 
6 to 10-weeks old female BALB/c mice (Charles River, Sulzfeld, Germany) were 
maintained under pathogen-free conditions with free access to food and water. 
They were allowed to adapt to the facility for at least one week before starting 
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the vaccination experiments. All animal experiments were handled in 
compliance with the European and national regulations for animal 
experimentation (European Directive 2010/63/EU; Animal Welfare Acts in 
Germany). Immunizations were performed with recombinant MVA-SARS-CoV-
2-S and non-recombinant MVA diluted in vaccination puffer (= saline, PBS). 
Mice vaccinated with saline served as a control. Two different concentrations 
(10*7 PFU and 10*8 PFU) and two different vaccination schemes (prime only, 
prime-boost: 21-day interval) were used by application into the quadriceps 
muscle of the left hind leg using the intramuscular route. Blood samples were 
collected on day 0, 18 and 35 post 1st immunization. To obtain serum, 
coagulated blood was centrifuged at 2,000 rpm for 10 min. The serum samples 
were stored at -20 °C. 
2.4.2. Transduction of vaccinated mice and challenge infection 
with SARS-CoV-2 (performed at the Institute of Virology, 
Philipps University Marburg) 
Mice were vaccinated as described in 2.4.1 Vaccination experiments and 
shipped to Prof. Dr. Stephan Becker`s lab at the Philipps University Marburg 
(Germany) for further experiments. Mice were isolated for at least one week to 
adapt to the facility. Mice were kept under anesthesia (ketamine/xylazine) and 
inoculated with 5x 10*8 PFU Adenovirus-ACE2-mCherry (cloned at ViraQuest 
Inc., North Liberty, IA, USA) using the intratracheal route. Three days post 
transduction, mice were infected with 1.5x 10*4 TCID50 SARS-CoV-2 
(BavPat1/2020 isolate, European Virus Archive Global #026V-03883) using the 
intranasal route. Mice were euthanized four days post infection and serum and 
tissue samples were taken for further analysis. 
2.4.3. Enzyme-linked immune sorbent assay (ELISA) 
SARS-CoV-2-S specific IgG titers were analyzed as described previously 
(KALODIMOU et al. 2019). Briefly, 96-well ELISA plates were coated with 
recombinant COVID-19 S protein (Full Length-R683A-R685A425 HisTag, 
ACROBiosystems, Newark, USA) o/n at 4 °C. Plates were washed with PBS 
and blocked with PBS (+ 1% BSA, 0.15 M sucrose) for 1 h at 37 °C. Heat-
inactivated mice sera were serially diluted three-fold in PBS (+ 1% BSA), 
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starting with a 1:100 dilution. ELISA plates were rinsed and mixed with the 
diluted mice sera and incubated for 1 h at 37 °C. Afterwards, plates were 
washed and probed with a goat anti-mouse IgG HRP antibody (diluted in PBS 
+ 1% BSA) for 1 h at 37 °C. After another wash step, 3´3´,5´5´- TMB Liquid 
Substrate System for ELISA was added and incubated until a color change was 
observed. The reaction was stopped with stop reagent for TMB substrate. The 
absorbance of each sample was measured at 450 nm with a 620 nm reference 
wavelength. A positive control was used to normalize the data and the control 
group (PBS) was used to set the cut-off value. Therefore, the mean value of the 
normalized OD values from the control group plus six standard deviations was 
determined. 
2.4.4. Prediction and generation of synthetic SARS-CoV-2-S 
peptides 
The Immune Epitope Database and Analysis Resource (IEDB) was used for 
epitope predication (CD8+T cell and CD4+ T cell) on the basis of the full-length 
SARS-CoV-2-S sequence (NCBI ID: QHD43416.1, Uniprot ID: P0DTC2 
(SPIKE_SARS2). The prediction was used only for the species “mouse” with 
the class I MHC alleles H2-Kd, H2-Dd and H2-Ld (CD8+ T cell) and the class II 
MHC alleles H2-IAd and H2-IEd (CD4+ T cell). To identify possible CD8+ T cell 
epitopes, the class I MHC Binding Prediction and class I MHC Processing 
Prediction tools (DHANDA et al. 2019; FLERI et al. 2017) were used, ending up 
with a long list of 9-11 amino acid long peptides restricted to a percentile rank 
cut-off of 10.0. Furthermore, all peptides with an IC50 score of ≤ 500 nM were 
selected for analysis using the class I MHC Processing Prediction tool 
“Proteasomal cleavage/TAP transport/MHC class I combined predictor. 
Peptides with a high score remained in the list of potential epitopes.  
 
To identify probable CD4+ T cell epitopes, the class II MHC Binding Prediction 
tool (DHANDA et al. 2019; FLERI et al. 2017) was used ending up with a list of 
15 amino acid long peptides. Peptides with a percentile rank of ≤10.0 and an 
IC50 rank of ≤1000 nM were selected for synthesis and testing. All peptides were 
obtained from Thermo Fisher Scientific (Planegg, Germany) as crude material. 
For further testing by ELISpot assay and ICS, the lyophilized peptides were 
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diluted in PBS or DMSO. In total, 19 potential CD8+ T cell and 15 CD4+ T cell 
epitopes were synthesized for further testing. 
2.4.5. Enzyme-linked immunosorbent Spot assay (ELISpot 
assay) 
ELISpot assay was performed to measure IFN-γ-producing T cells (VEIT et al. 
2018). At day eight post prime or prime-boost vaccination, mice were 
euthanized and whole splenocytes were prepared. Cell suspensions were 
prepared by passing spleens through a 70 µm strainer and lysed with Red Blood 
Cell Lysis Buffer. Cells were centrifuged for 5 min at 1,500 rpm, washed twice 
and resuspended in RPMI 1640 medium (+ 10% FBS, 1% 
penicillin/streptomycin, 1% HEPES). ELISpot assay was performed according 
to the manual. Briefly, 2x 10*5 splenocytes were seeded in 96-well plates and 
stimulated with the peptides (2 µg/ml in RPMI medium). Non-stimulated cells 
and cells stimulated with PMA/ionomycin or Vaccinia virus peptide SPGAAGYD 
(F2(G)26-34; H-2L
d) (TSCHARKE et al. 2005) served as controls. Cells were 
cultured for 48 h at 37 °C and afterwards stained according to the manual. Spots 
were counted for further analysis by an automated ELISpot plate reader. 
2.4.6. Intracellular cytokine staining (ICS) 
Intracellular cytokine staining was performed as described before 
(KALODIMOU et al. 2019). Briefly, splenocytes were isolated as described in 
chapter 2.4.5. Enzyme-linked immunosorbent Spot assay. Cells were 
stimulated with 8 µg/ml S269-278 peptide or Vaccinia virus peptide F226-34 to 
analyze SARS-CoV-2-S- or MVA-specific CD8+ T cell responses. Splenocytes 
stimulated with PMA/ionomycin were used as positive controls whereas 
splenocytes stimulated with RMPI medium were used as a negative control. 
After 2 h at 37 °C, brefeldin A was added and cells were cultured for 4 h at 37 
°C. The stimulated cells were washed with FACS buffer (+ 2% FBS) and stained 
with anti-mouse CD3 phycoerithrin (PE)-Cy7, anti-mouse CD4 542 Brilliant 
Violet, anti-mouse CD8α Alexa Fluor 488 and CD16/CD32 for 30 min on ice. 
Cells were washed and fixed with fixation buffer for 20 min on RT, resuspended 
in FACS buffer and stored at 4 °C o/n. The next day, cells were permeabilized 
by using intracellular staining permeabilization wash buffer and stained with 
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anti-mouse IFN-γ diluted in perm wash buffer for 30 min at RT. Afterwards, cells 
were washed and resuspended in FACS buffer and data were acquired by 
MACSQuant VYB Flow Analyser. Analysis was performed by using the software 
FlowJo. 
2.5. Statistical analysis 
Data were analyzed using GraphPad Prism 5.0 (GraphPad Sodtware Inc., San 
Diego, CA, USA) and were expressed as mean ± standard error of the mean 
unless stated otherwise. Statistical analysis was performed using unpaired two-
tailed t test to compare two groups. Comparison of three or more groups was 
analyzed by one-way ANOVA and Tukey post-hoc test. P-values less than 0.05 
were considered to be statistically significant. 
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V. OBJECTIVES 
The global pandemic caused by SARS-CoV-2 is still present, affecting the daily 
life of millions of people. Due to the lack of approved therapies and the need for 
more vaccines against SARS-CoV-2, this work describes the following 
milestones in the development of the new candidate vaccine MVA-SARS-CoV-
2-S:  
 
(i) Generation of recombinant MVA expressing the full-length 
SARS-CoV-2 spike protein (MVA-SARS-CoV-2-S). 
 
(ii) In vitro characterization of recombinant MVA-SARS-CoV-2-S 
 
a. Genome analysis and stability testing 
b. Protein expression  
c. Replication capacity 
 
(iii) In vivo characterization of recombinant MVA-SARS-CoV-2-S in 
terms of adaptive immune response in BALB/c mice 
 
a. Immunization experiments  
b. Determination of SARS-CoV-2-S specific CD8+ and CD4+ 
T cell epitopes 
c. Humoral immune response against SARS-CoV-2, 
including analysis of binding and neutralizing antibodies 
d. Protective capacity of MVA-SARS-CoV-2-S upon 
challenge infection 
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VI. RESULTS 
1. Construction and characterization of 
recombinant MVA-SARS-CoV-2-S 
1.1. Construction of recombinant MVA-SARS-CoV-2-S 
To generate the recombinant MVA-SARS-CoV-2-S (MVA-S), the encoding 
sequence of the spike protein from the virus isolate Wuhan HU-1 (GenBank 
accession no. MN908947.1) served as a template. In addition, modifications 
including an HA-tag and codon optimization were made. For the latter, G/C-runs 
and TTTTTNT regions were changed on the genomic level without affecting the 
amino acid sequence. Furthermore, restriction sites (PmeI and NotI) were 
added for cloning the SARS-CoV-2-S sequence into the MVA vector plasmid 
pIIIPmH5red.  
 
The cDNA was placed under the transcriptional control of the Vaccinia virus 
early/late PmH5 promoter (WYATT et al. 1996) by integration of the sequence 
into the MVA vector plasmid pIIIPmH5red. The new plasmid, pIIIPmH5red-
SARS-CoV-2-S contains a resistance gene (AmpR), flank regions (flank-1 and 
flank-2) of MVA genomic DNA and the reporter gene mCherry (Figure 9). 
Correct insertion and identity of the SARS-2-S sequence was confirmed by 
sequencing. 
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Figure 9: Vector plasmid pIIIH5red-SARS-CoV-2-S. The sequence of SARS-CoV-2-S (blue) was cloned 
between flanking regions (flank-1 and flank-2, orange) for homologous recombination into deletion site III 
of the MVA genome. The marker gene mCherry (red) was placed between two flanks (orange) for 
intragenomic homologous recombination during plaque purification. The resistance gene AmpR (blue) was 
used for selection of positive clones after integration of the SARS-CoV-2-S sequence into the plasmid. 
 
The encoding sequence of SARS-CoV-2-S was introduced into deletion site III 
of MVA-F6-sfMR by homologous recombination between MVA DNA sequences 
adjacent to deletion site III in the MVA genome and copies cloned into plasmid 
pIIIPmH5red-SARS-2-S (flank-1 and flank-2). Recombinant MVA-SARS-CoV-
2-S was obtained by plaque purification using the co-expressed fluorescent 
protein mCherry. The latter was removed by intragenomic homologous 
recombination during plaque purification and amplification of the recombinant 
virus (marker gene deletion) (Figure 10). 
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Figure 10: Construction of recombinant MVA-SARS-CoV-2-S. Schematic diagram of the MVA genome 
including the six major deletion sites I-VI. The encoding sequence of SARS-CoV-S was introduced into 
the deletion site III by homologous recombination. Deletion of the marker gene mCherry occurred by 
intragenomic homologous recombination. 
1.2. Genetic characterization and stability of the SARS-
CoV-2 spike sequence 
Viral DNA was isolated and further analyzed in regard to correct insertion and 
genomic integrity of the SARS-CoV-2-S sequence. In addition, correct removal 
of the marker gene mCherry as well as the integrity of the C7L gene region were 
tested. The latter encodes a regulatory Vaccinia virus protein, which is important 
for viral gene expression in mammalian cells (BACKES et al. 2010; MEYER et 
al. 1991; NÁJERA et al. 2006). Therefore, different control PCRs were 
performed, as described previously (SONG et al. 2013; VEIT et al. 2018).  
 
The correct length of the insert could be shown by amplifying a PCR product of 
about 4.8 kb (Figure 11a). The correct removal of mCherry could be shown by 
comparing the PCR product from pIIIH5red-SARS-CoV-2-S (pIII-S) with the 
recombinant MVA-SARS-CoV-2-S (MVA-S). A difference of ~1.0 kb in size 
corresponds to the size of mCherry. The absence of non-recombinant MVA 
could be shown by the lack of the characteristic amplicon of 0.762 kb. Specific 
oligonucleotides binding inside the insert region were designed, allowing an 
amplification of overlapping amplicons with sizes of 0.714 kb, 0.954 kb, 1.341 
kb and 1.689 kb (Figure 11b). Next, the C7L specific PCR was performed 
verifying that the recombinant MVA-SARS-CoV-2-S shows no difference to non-
recombinant MVA (Figure 11c).  
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Figure 11: Genetic integrity of MVA-SARS-CoV-2-S (MVA-S). Genomic DNA was analyzed for correct 
insertion into (a) deletion site III, (b) correct size of the insert, and (c) genetic integrity of the C7L region. 
(a) line 1: H2O control. line 2: non-recombinant MVA. line 3: pIIIPmH5red-SARS-CoV-2-S (pIII-S). line 4: 
recombinant MVA-SARS-CoV-2-S (MVA-S). The absence of non-recombinant MVA was demonstrated by 
the lack of a specific DNA fragment (0.762 kb). Removal of the marker gene mCherry was shown by the 
reduced size (~1.0 kb) of recombinant MVA-S compared to pIII-S. (b) line 1: H2O control. line 2: non-
recombinant MVA. line 3-6: overlapping amplicons to cover full-length S protein. (c) line 1: H2O control. 
line 2: non-recombinant MVA. line 3: MVA-SARS-CoV-2-S (MVA-S).  
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To confirm genetic integrity, recombinant MVA-SARS-CoV-2-S was passaged 
five times on DF-1 cells at a MOI of 0.05 (“low MOI passage”). Afterwards, 
genomic analysis and stable protein expression were further validated. In 
regard of genomic analysis, the six deletion PCRs of passage 1 and passage 5 
were performed by using oligonucleotides that bind to the flank regions of the 
six major MVA deletions sites I-VI. No difference could be observed between 
passage 1 and passage 5 in terms of stability of the SARS-CoV-2-S sequence 
(Figure 12).  
 
 
Figure 12: Genetic stability of the six major deletion sites of MVA-SARS-CoV-2-S (MVA-S) following 
serial passages on DF-1 cells. Viral DNA was isolated and tested for stability of the six major deletion 
sites after serially passaging MVA-S on DF-1 cells for (a) one time or (b) five times. (a, b) line 1: deletion 
site I. line 2: deletion site II. line 3: deletion site III. line 4: deletion site IV. line 5: deletion site V. line 6: 
deletion site VI. line 7: H2O control.  
 
To screen for stable protein expression following low MOI passage, 
immunostaining was conducted (Figure 13). A total of 60 clonal MVA-S isolates 
were collected after the fifth passage on DF-1 cells and used to infect DF-1 cells 
grown on 24-well tissue culture plates. Cells infected with non-recombinant 
MVA were used as control. Cells were incubated for 48 h and stained with anti-
Vaccinia and anti-HA antibodies. Plaques were counted and 60/60 MVA-S 
isolates were tested positive for unimpaired expression of the recombinant 
SARS-CoV-2-S protein. 
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Figure 13: Low MOI passage of recombinant MVA-SARS-CoV-2-S (MVA-S). Recombinant MVA-S was 
serially passaged on DF-1 cells and unimpaired recombinant gene expression was screened by 
immunostaining using an antibody directed against the HA-tag. 
1.3. Protein expression of full-length SARS-CoV-2 spike 
protein 
To evaluate the expression pattern of the recombinant spike protein, Vero E6 
cells were infected with recombinant MVA-SARS-CoV-2-S (MVA-S) and 
stained with antibodies directed against the HA-tag or the spike protein and 
were further analyzed using fluorescence microscopy. The antibody directed 
against the HA-tag at the C-terminal part of the recombinant spike protein 
showed specific staining in permeabilized cells, which corresponds to the 
expected intercellular localization of the C-terminus of the SARS-CoV-2-S 
protein. The SARS-CoV-1/SARS-CoV-2 specific antibody recognizes a region 
in the external domain of the spike protein and allows staining in non-
permeabilized cells, which indicates a translocation of the SARS-CoV-2-S 
protein to the cytoplasm membrane (Figure 14). 
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Figure 14: Immunostaining of SARS-CoV-2 spike protein in MVA-SARS-CoV-2-S (MVA-S) infected 
Vero E6 cells. Cells were infected at a MOI of 0.5 with recombinant MVA-S or non-recombinant MVA 
(control) and fixed with paraformaldehyde. Permeabilized and non-permeabilized cells were probed with 
antibodies directed against the HA-tag or the spike protein and further stained with a secondary antibody 
to perform S-specific fluorescent staining (red). Cell nuclei were counterstained using DAPI (blue). 
 
In addition, the recombinant spike protein was examined in more detail by using 
Western Blot analysis. Vero E6 cells were infected with recombinant MVA-
SARS-CoV-2-S and non-recombinant MVA (control) and lysates were prepared 
after certain time-points to screen for protein expression over time. The proteins 
were separated by SDS-PAGE according to their sizes and stained with a 
specific antibody directed against the HA-tag. Two prominent bands at 190 kDa 
and 90-100 kDa could be observed (Figure 15). The higher band might refer to 
the full-length spike protein whereas the lower band might refer to the S2 
cleavage product as the HA-tag is located at the C-terminal part of the spike 
protein. Due to the early transcription of SARS-CoV-2-S by the MVA PmH5 
promoter, high protein amounts were already detectable two hours post 
infection, continuously increasing until 24 hours post infection. The expected 
size of SARS-CoV-2-S is around 145 kDa which leads to the hypothesis that 
the spike protein might be glycosylated. Indeed, NetNGlyc 1.0 server analysis 
indicated at least 17 N-glycosylation sites for co- and post-translational 
modifications. The treatment of cell lysates with PNGase F, which removes all 
N-linked oligosaccharide chains, reduced the molecular masses of the 
recombinant SARS-CoV-2-S protein bands from 190 kDa to 145 kDa and from 
90-100 kDa to 65 kDa, perfectly matching the expected sizes of unmodified full-
length SARS-CoV-2-S and the S2 cleavage product (Figure 15).  
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Figure 15: Synthesis of full-length spike protein in MVA-SARS-CoV-2-S (MVA-S) infected Vero E6 
cells. Cells were infected at a MOI of 10 and collected after the indicated time points. Furthermore, 
deglycosylation of the S protein was performed using PNGase F (MVA-Sd). Polypeptides were separated 
by SDS-PAGE and analyzed with an antibody directed against the HA-tag. Lysates from non-infected 
(Mock) or non-recombinant MVA infected (MVA) cells were used as controls. 
1.4. Growth kinetics on permissive and non-permissive 
cell lines 
Beside genomic stability and stable expression of SARS-CoV-2-S, another 
important feature of (recombinant) MVA is the replication deficiency in 
mammalian cell lines. To confirm the replication deficiency, a multiple-step 
growth analysis on various mammalian cell lines was performed. Three cell 
lines of human origin (HaCat, HeLa, and A549 cells) were infected with 
recombinant MVA-SARS-CoV-2-S (MVA-S) and non-recombinant MVA 
(control) and collected after the indicated time points. Furthermore, the avian 
cell line DF-1, which was used to amplify the recombinant MVA-S, served as a 
control cell line permissive for MVA growth. No virus replication could be 
observed in human cell lines up to 72 hours post infection. In DF-1 cells, 
however, recombinant MVA-S productively amplified to levels comparable with 
non-recombinant MVA (Figure 16). 
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Figure 16: Multiple-step growth analysis of recombinant MVA-SARS-CoV-2-S (MVA-S) and non-
recombinant MVA (MVA). Cells were infected at a MOI of 0.05 with MVA-S or MVA and collected at the 
indicated time points. Titration was performed on CEF cells and plaque-forming units (PFU) were 
determined. MVA-S and MVA could be amplified on DF-1 cells but failed to replicate on all tested cells of 
human origin (HaCat, HeLa, and A549 cells). 
2. Immune response 
2.1. Determination of a potential CD8+ T cell epitope 
Information about antigen specificities of SARS-CoV-2-S specific T cells is 
limited. Due to that, the IEDB was used for selection of putative S-specific 
peptide epitopes for activation of CD8+ T cell and CD4+ T cell response. The 
predicted peptides were divided into pools of three to six peptides. BALB/c mice 
were vaccinated with 10*8 PFU and euthanized eight days post prime 
immunization. Splenocytes were further processed to test the activation 
capacity of different peptide pools. Several peptide pools showed responses 
above the background signal (Figure 17a) and, after testing single peptides, 
the immunodominant SARS-CoV-2 S H2-Kd epitope S269-278 (GYLQPRTFL; S1 
N-terminal) could be identified (Figure 17b).  
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Figure 17: Identification of H2-d restricted T cell epitopes of the SARS-CoV-2-S protein. BALB/c 
mice (n= 4-6) were immunized once with 10*8 PFU MVA-SARS-CoV-2-S (MVA-S) or non-recombinant 
MVA (MVA) via the i.m. route. Splenocytes were collected and further processed eight days post 
immunization and stimulated with pools of peptides (9-12 mer) or single peptides from positive pools and 
were analyzed by IFN-γ ELISPOT assay. (a) IFN-γ spot forming-cells (SFC) measured by ELISpot assay 
after stimulation with peptide pools. (b) IFN-γ SFC measured by ELISpot assay after stimulation of single 
peptides from the two most promising pools P4 and P9. Statistical differences between MVA-S and MVA 
groups were analyzed by unpaired two-tailed t tests. Asterisks represent statistically significant differences 
between the groups. * p < 0.05, ** p < 0.01, **** p < 0.0001 
 
The predicted CD4+ T cell epitopes were not tested in the prime only schedule, 
but were included as pools of three to six peptides to test CD4+ T cell response 
upon prime-boost vaccination (chapter 2.2.1. Spike specific CD8+ and CD4+ T 
cell response)  
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2.2. T cell response 
To assess the S-antigen specific T cell response (CD8+ and CD4+) upon 
vaccination with MVA-SARS-CoV-2-S, two different vaccination schedules 
(prime only, prime-boost) with two different doses (low dose: 10*7 PFU and high 
dose: 10*8 PFU) were performed (Figure 18). 
 
 
Figure 18: Schematic diagram of two immunization schedules (prime only and prime-boost) with 
MVA-SARS-CoV-2-S (MVA-S) to test T cell responses. Groups of BALB/c mice (n=4-6) were vaccinated 
with 10*7 PFU (low dose) or 10*8 PFU (high dose) of MVA-S via the i.m. route using a prime only or prime-
boost schedule. T cell responses were examined at day eight post 1st immunization (prime only) or 2nd 
immunization (prime-boost). Created with BioRender.com 
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2.2.1.  Spike specific CD8+ and CD4+ T cell response 
S-antigen specific CD8+ T cell response was determined by IFN-γ ELISpot 
assay and intracellular cytokine staining (ICS). Splenocytes of mice vaccinated 
according to the prime only or prime-boost schedule were isolated at day eight 
post last immunization and stimulated with the immunodominant SARS-CoV-2-
S H2-Kd epitope S269-278. A single application of MVA-SARS-CoV-2-S (MVA-S) 
induced detectible levels of S269-278 epitope-specific induced CD8+ T cells with 
mean numbers of 342 IFN-γ spot-forming-cells (SFC) in splenocytes for the low 
dose and 275 SFC for the high dose. Mice vaccinated with non-recombinant 
MVA showed no detectible SFC (Figure 19a). 
 
 
Figure 19: Activation of SARS-CoV-2-S specific CD8+ T cell response after prime only 
immunization with MVA-SARS-CoV-2-S (MVA-S). Groups of BALB/c mice (n= 4-6) were immunized 
once with 10*7 or 10*8 PFU MVA-S using the i.m. route. Mice vaccinated with non-recombinant MVA were 
used as controls. Splenocytes were collected and isolated at day eight post immunization and stimulated 
with the H2d restricted peptide of the SARS-CoV-2-S protein S268-276 and measured by (a) IFN-γ ELISpot 
assay and (b-d) IFN-γ and TNF-α ICS plus FACS analysis. (b, c) IFN-γ produced by CD8+ T cells 
measured by FACS analysis. Graphs show (b) frequency and (c) absolute number of IFN-γ producing 
CD8+ T cells. (d) cytokine profile of S268-276 specific CD8+ T cells. Graphs show the mean frequency of 
IFN-γ-TNF-α+, IFN-γ+ TNF-α+ and IFN-γ+ TNF-α- cells within the positive CD8+ T cell population.  
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Intracellular cytokine staining (ICS) for IFN-γ was performed to complement the 
ELISpot results, showing mean values of 0.32% (high dose) and 0.36% (low 
dose) IFN-γ positive splenic CD8+ T cells (Figure 19b). The absolute numbers 
of IFN-γ positive CD8+ T cells were 27,487 (low dose) and 34,294 (high dose). 
Mice vaccinated with non-recombinant MVA showed no detectible number of 
IFN-γ positive CD8+ T cells (Figure 19c). Substantial numbers of IFN-γ positive 
CD8+ T cells showed co-expression of TNF-α, with mean values of 61.7% (low 
dose) and 68.7% (high dose) from total IFN-γ expressing cells (Figure 19d). No 
significant difference between the two doses could be observed for the prime 
only schedule in terms of the CD8+ T cell response. 
 
The second immunization at day 21 with 10*7 PFU (low dose) or 10*8 PFU 
(high dose) of MVA-SARS-CoV-2-S increased the number of S-specific CD8+ 
T cells. At day eight post second immunization, splenocytes were isolated and 
stimulated with the immunodominant SARS-CoV-2 S H2-Kd epitope S269-278. 
ELISpot analysis revealed mean numbers of 1,020 IFN-γ SFC (low dose) and 
1,159 IFN-γ SFC (high dose) in vaccinated animals. Mice vaccinated with saline 
(PBS) showed no SFC (Figure 20a).  
 
Intracellular cytokine staining revealed mean values of 0.62 % (high dose) and 
0.60% (low dose) IFN-γ positive splenic CD8+ T cells (Figure 20b) and total 
numbers of 40,873 (low dose) and 49,553 IFN-γ positive CD8+ T cells (Figure 
20c). As already seen for the prime only immunization, a high proportion of IFN-
γ positive CD8+ T cells co-expressed TNF-α (~70% for low and high dose) 
(Figure 20d). 
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Figure 20: Activation of SARS-CoV-2-S specific CD8+ T cell response after prime- boost 
immunization with MVA-SARS-CoV-2-S (MVA-S). Groups of BALB/c mice (n=4) were immunized twice 
with 10*7 or 10*8 PFU of MVA-S over a 21-day interval using the i.m. route. Mice vaccinated with saline 
(PBS) served as controls. Splenocytes were collected and isolated at day eight post boost immunization 
and stimulated with the H2d restricted peptide of the SARS-2-S protein S268-276 and measured by (a) IFN-
γ ELISpot assay and (b-d) IFN-γ and TNF-α ICS plus FACS analysis. (b, c) IFN-γ produced by CD8+ T 
cells measured by FACS analysis. Graphs show (b) frequency and (c) absolute number of IFN-γ producing 
CD8+ T cells. (d) cytokine profile of S268-276 specific CD8+ T cells. Graphs show the mean frequency of 
IFN-γ-TNF-α+, IFN-γ+ TNF-α+ and IFN-γ+ TNF-α- cells within the positive CD8+ T cell population. 
Differences between the groups were analyzed by one-way ANOVA and Tukey post-hoc test. Asterisks 
represent statistically significant differences between the groups. * p < 0.05, ** p < 0.01 
 
Moreover, activation of S-specific CD4+ T cells was analyzed. The predicted 
epitopes for MHC II binding were tested after a prime-boost immunization with 
low dose (10*7 PFU) or high dose (10*8 PFU) of MVA-SARS-CoV-2-S. 
Splenocytes were collected at day eight post 2nd immunization and stimulated 
with three pools containing three to six peptides (15 mer). The presence of small 
amounts of S-specific CD4+ T cells could be demonstrated with mean values 
of 10-20 SFC (low dose) and 16-25 SFC (high dose) (Figure 21). 
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Figure 21: Analysis of predicted peptides to activate CD4+ T cell response upon prime-boost 
vaccination with MVA-SARS-CoV-2-S (MVA-S). Groups of BALB/c mice (n= 4-6) were immunized twice 
over a 21-day interval with 10*7 PFU or 10*8 PFU MVA-S using the i.m. route. Mice vaccinated with saline 
(PBS) served as controls. Splenocytes were collected and isolated at day eight post 2nd immunization and 
stimulated with three different pools (three to six peptides/pool) containing 15 mer peptides. IFN-γ spot-
forming cells (SFU) were measured by ELISpot assay. 
2.2.2. MVA-specific CD8+ T cell response 
The MVA-specific immunodominant CD8+ T cell epitope F2(G)26-34 served as a 
control for detection and analysis of MVA vector-specific CD8+ T cell response 
in BALB/c mice. A single application of MVA-SARS-CoV-2-S (MVA-S) induced 
substantial levels of F2(G)26-34 epitope-specific CD8+ T cells with mean values 
of 337 IFN-γ SFC (low dose) and 496 IFN-γ SFC (high dose). Mice vaccinated 
with non-recombinant MVA showed mean values of 477 IFN-γ SFC (low dose) 
and 481 IFN-γ SFC (high dose) (Figure 22a). Intracellular cytokine staining 
revealed values of 0.39% (low dose) and 0.26% (high dose) IFN-γ positive 
CD8+ T cells in the spleen (Figure 20b) and total numbers of 33,310 (low dose) 
and 16,624 (high dose) IFN-γ positive CD8+ T cells (Figure 22c). Mice 
vaccinated with non-recombinant MVA showed mean values of 0.37% (low 
dose) and 0.22% (high dose) IFN-γ positive splenic CD8+ T cells (Figure 22b) 
and total numbers of 32,777 (low dose) and 16,672 (high dose) IFN-γ positive 
CD8+ T cells (Figure 22c). A high proportion of IFN-γ positive CD8+ T cells 
also co-expressed TNF-α (68.5% for low dose and 37.7% for high dose) in mice 
vaccinated with MVA-S. In the control group mean values of 77.4% (low dose) 
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and 47.6% (high dose) of IFN-γ+ TNF-α+ CD8+ T cells were observed. 
 
 
Figure 22: Induction of MVA-specific CD8+ T cell response upon prime immunization with MVA-
SARS-CoV-2-S (MVA-S). Groups of BALB/c mice (n=4-6) were vaccinated once with 10*7 PFU (low 
dose) or 10*8 PFU (high dose) MVA-S. Mice vaccinated with non-recombinant MVA were used as controls. 
Splenocytes were collected at day eight post immunization and stimulated with the H2d restricted MVA-
specific peptide F2(G)26-34. Measurement of IFN-γ was performed by IFN-γ ELISpot assay and IFN-γ and 
TNF-α ICS plus FACS analysis. (a) IFN-γ spot-forming-cells (SFC) for splenocytes analysis by ELISpot 
assay. (b) percentage of CD8+ T cells producing IFN-γ. (c) absolute number of CD8+ T cells producing 
IFN-γ. (d) cytokine profile of CD8+ T cells stimulated by MVA-specific F2(G)26-34 peptide. Graph shows 
mean frequency of IFN-γ- TNF-α+, IFN-γ+ TNF-α+ and IFN-γ+ TNF-α- cells within the positive CD8+ T 
cell population. 
 
The second immunization at day 21 with 10*7 PFU (low dose) or 10*8 PFU 
(high dose) MVA-S increased the number of MVA-specific CD8+ T cells. At day 
eight post 2nd immunization, splenocytes were collected and stimulated with the 
MVA-specific F2(G)26-34 peptide. ELISpot analysis revealed mean numbers of 
1,054 IFN-γ SFC (low dose) and 1,230 IFN-γ SFC (high dose) in vaccinated 
animals. Mice vaccinated with saline (PBS) showed no SFC (Figures 23a). 
Intracellular cytokine staining revealed mean values of 0.70% (high dose) and 
0.64% (low dose) IFN-γ positive splenic CD8+ T cells (Figure 23b) and total 
numbers of 48,733 (low dose) and 61,620 IFN-γ positive CD8+ T cells (Figure 
23c). As already seen for the prime only immunization, a high proportion of IFN-
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γ positive CD8+ T cells co-expressed TNF-α (~70% for low and high dose) 
(Figure 23d). 
 
 
Figure 23: Induction of MVA-specific CD8+ T cell response upon prime-boost vaccination (21-day 
interval) with MVA-SARS-CoV-2-S (MVA-S). Groups of BALB/c mice (n=4) were immunized twice with 
10*7 PFU (low dose) or 10*8 PFU (high dose) MVA-S over a 21-day interval. Mice vaccinated with saline 
(PBS) were used as controls. Splenocytes were collected at day eight post 2nd immunization and 
stimulated with the H2d restricted MVA-specific peptide F2(G)26-34. Measurement of IFN-γ was performed 
by IFN-γ ELISpot assay and IFN-γ and TNF-α ICS plus FACS analysis. (a) IFN-γ spot-forming- cells (SFC) 
for splenocytes analysis by ELISpot assay. (b) percentage of CD8+ T cells producing IFN-γ. (c) absolute 
number of CD8+ T cells producing IFN-γ. (d) cytokine profile of CD8+ T cells stimulated by MVA-specific 
F2(G)26-34 peptide. Graph shows mean frequency of IFN-γ- TNF-α+, IFN-γ+ TNF-α+ and IFN-γ+ TNF-α- 
cells within the positive CD8+ T cell population. Differences between the groups were evaluated by one-
way ANOVA and Tukey post-hoc test. Asterisks represent statistically significant differences between the 
groups. * p < 0.05, ** p < 0.01. 
2.3. Spike specific humoral immune response 
To evaluate the S-antigen specific humoral immune response upon vaccination 
with MVA-SARS-CoV-2-S (MVA-S), BALB/c mice were vaccinated twice with 
10*7 PFU (low dose) or 10*8 PFU (high dose) MVA-S over a 21-day interval. 
Serum samples were collected at day 18 post 1st immunization and at day 14 
post 2nd immunization (Figure 24). 
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Figure 24: Schematic diagram of prime-boost immunization schedule with MVA-SARS-CoV-2-S 
(MVA-S) to test humoral immune response. Groups of BALB/c mice (n=7-12) were vaccinated twice 
with 10*7 PFU (low dose) or 10*8 PFU (high dose) MVA-S via the i.m route. Serum samples were collected 
at day 18 post 1st immunization and at day 14 post 2nd immunization and tested for S-antigen specific B 
cell response. Created with BioRender.com  
 
Serum samples from immunized mice were tested for serum IgG antibodies by 
ELISA using full-length SARS-CoV-2 spike protein as the antigen. A single 
application led to seroconversion in 3/8 low dose vaccinated and 4/6 high dose 
vaccinated mice. A second immunization led to seroconversion in all vaccinated 
mice, showing mean titers of 1:900 (low dose) and 1:1,257 (high dose). No S-
specific antibodies could be detected in mice vaccinated with saline (PBS) 
(Figure 25a). 
 
In addition, the neutralizing capacity was further validated by using a virus 
neutralizing assay (VNT100). Following a single application of MVA-S, no 
neutralizing activity could be found in low dose or high dose vaccinated mice 
with a VNT100 assay. A second immunization led to neutralizing activity in 79% 
of all sera from vaccinated mice (low dose and high dose) with average 
reciprocal VNT100 titers of 19.8 (low dose) and 105.8 (high dose). Mice 
vaccinated with saline (PBS) showed no detectible levels of neutralizing 
antibodies (Figure 25b). 
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Figure 25: S-antigen specific humoral immune response induced upon vaccination with MVA-
SARS-CoV-2-S (MVA-S). Groups of BALB/c mice (n= 7-12) were vaccinated twice with 10*7 PFU (low 
dose) or 10*8 (high dose) MVA-S over a 21-day interval using the i.m. route. Mice vaccinated with saline 
(PBS) were used as a control. Serum samples were collected at day 18 post 1st immunization and at day 
14 post 2nd immunization and tested for (a) SARS-CoV-2-S specific IgG titers by ELISA and SARS-CoV-
2 neutralizing antibodies by (b) virus neutralization (VNT100). VNT100 assay was performed by Prof. Dr. 
Stephan Becker`s lab. 
2.4. Protective capacity upon challenge infection  
To determine the protective capacity of the MVA-SARS-CoV-2-S (MVA-S) 
vaccine, an adenoviral transduction-based model was used, as described 
before (SUN et al. 2020a; WONG et al. 2020). Immunized BALB/c mice (MVA-
S or PBS as control) were intratracheally transduced with 5x10*8 PFU of an 
adenoviral vector two weeks after the second immunization. The adenoviral 
vector expresses the human ACE2 receptor and the reporter protein mCherry 
(ViraQuest Inc., North Liberty, IA, USA). Three days later, mice were challenged 
by infection with 1.5x10*4 TCID50 SARS-CoV-2 (isolate BavPat1/2020 isolate, 
European Virus Archive Global # 026V-03883). Four days later, mice were 
euthanized and the viral load was measured in blood samples and lung tissue 
samples (Figure 26).  
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Figure 26: Vaccination schedule prime-boost, following transduction with AdV-ACE2-mCherry and 
challenge infection with SARS-CoV-2. BALB/c mice were vaccinated with MVA-SARS-CoV-2-S (10*7 
or 10*8 PFU) over a 21-day interval. At day 35, mice were inoculated with 5x 10*8 PFU AdV-ACE2-
mCherry. Three days later, mice were infected with 1.4x 10*4 TCID50 SARS-CoV-2 using the intranasal 
route. At day 43, four days after the infection, mice were euthanized and serum samples and tissue 
samples were collected. Created with BioRender.com  
 
The control group showed elevated amounts of viral RNA (>1000 SARS-CoV-
2 genome equivalents/ng of total RNA), whereas the lung tissue samples of 
mice vaccinated with low or high dose MVA-SARS-CoV-2-S showed no 
detectible amount of viral RNA (<100 genome equivalents/ng of total RNA) 
(Figure 27a). To confirm adenoviral vector transduction took place, real-time 
RT-PCR analysis of co-expressed mCherry was performed, showing 
comparable levels of mCherry in all three groups (Figure 27b). Moreover, high 
levels of SARS-CoV-2 (>1000 TCID50/ml) could be detected in lung tissue 
samples of the control group, whereas no replicative SARS-CoV-2 could be 
detected in mice vaccinated with low dose or high dose of MVA-SARS-CoV-2 
(Figure 27c). Furthermore, using a VNT100 assay, neutralizing antibodies could 
be detected in the sera of the vaccinated groups (10/11) but not in the control 
group (0/4) (Figure 27d). 
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Figure 27: Protective capacity of MVA-SARS-CoV-2-S (MVA-S) immunization. Groups of BALB/c 
mice (n=4-6) were immunized twice with MVA-S (10*7 or 10*8 PFU) over a 21-day interval. Mice 
immunized with PBS served as a control. At day 43, mice were euthanized and lung tissue samples were 
tested for (a) viral load (genome copies/ng of total RNA), (b) the expression level of reporter gene mCherry 
(mRNA copies/ng of total RNA) and (c) the amount of replicative SARS-CoV-2 (TCID50/ml). Serum 
samples were analyzed for neutralizing antibodies (VNT100) (d). Statistical analysis was performed by 
one-way ANOVA and Tukey post-hoc test and the statistical significance of differences between 
vaccinated groups and control group is indicated as follows *, p < 0.05, ***, p < 0.001. Experiments were 
performed by Prof. Dr. Stephan Becker`s lab. 
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VII. DISCUSSION 
Since COVID-19 became a global pandemic in 2020, tremendous efforts have 
been undertaken by researchers worldwide to develop suitable treatments and 
efficient vaccines against severe acute respiratory syndrome coronavirus 2 
(SARS-CoV-2). Prophylactic immunization of people with high risk for 
infections, including healthcare personal, elderly or people with pre-existing 
illnesses, should be performed to combat the global spread of SARS-CoV-2. 
SARS-CoV-2 spike (S) protein has been chosen as an antigen for vaccine 
development by many researchers, as published data from other coronaviruses 
indicated potential cytotoxic T cell and B cell response, including neutralizing 
antibodies (BISHT et al. 2004; SONG et al. 2013; VEIT et al. 2018; YANG et al. 
2004). With beginning of 2021, several spike protein-based vaccines are in 
preclinical or clinical trials. Two mRNA vaccines and one replication-deficient 
simian adenovirus expressing the full-length S protein are already licensed and 
used as a prevention of COVID-19 in Europe. However, little is known about 
long-living immunity and with the spread of new virus variants (ECDC 2020; 
WHO 2020), suitable and broad-reactive vaccines are urgently needed.  
 
Modified Vaccinia virus Ankara (MVA), an attenuated vaccinia virus strain 
(VACV), lacking virulence factors and immune evasion proteins, is broadly used 
as a vector platform to develop vaccines against various viral and bacterial 
infections. In this study, a recombinant MVA expressing the full-length SARS-
CoV-2 spike (S) protein was generated to investigate S-specific humoral and 
cell-mediated immune responses in BALB/c mice. Thereby, the activation of 
CD4+ and CD8+ T cells as well as circulating antibodies upon vaccination with 
two doses of recombinant MVA-SARS-CoV-2-S (MVA-S) was demonstrated. 
Protective capacity tested with an adenoviral transduction model revealed first 
promising data for protection from a SARS-CoV-2 infection. In addition, the 
compatibility with clinical use and a potential industrial large-scale production 
could be confirmed. Therefore, replication efficiency on DF-1 cells, an optimized 
cell line for manufacturing process, was confirmed. Moreover, stable expression 
of the full-length spike protein upon serial passages of MVA-SARS-CoV-2-S at 
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low MOI was demonstrated. Taken together, these data demonstrate that 
recombinant MVA-S might be a promising candidate vaccine against SARS-
CoV-2. 
 
Vaccine-induced immunity vs. viral infection 
Vaccination remains the most efficient way to prevent infectious diseases, as 
seen by the remarkable success of vaccines against diphtheria, tetanus, polio 
and smallpox (PLOTKIN 2008). The global burden of infectious diseases could 
be reduced, and in the case of smallpox, completely eradicated by vaccination 
(BREMAN and ARITA 2011). However, vaccine development is still a 
challenging area of research since by now, no licensed vaccines are available 
for several life-threatening infectious pathogens such as HIV (JOHNSTON and 
FAUCI 2007; McMICHAEL et al. 2009) and Plasmodium falciparum (HILL 
2006). The protective capacity of vaccines is based on the induction of 
immunological memory responses, which combat an infection or re-infection 
with a certain pathogen (SALLUSTO et al. 2010). The protective capacity of 
most of the licensed vaccines is related to a strong humoral immunity, 
determined by high levels of neutralizing antibodies on the mucosal surfaces or 
in serum of vaccinated individuals (PLOTKIN 2008). Strong humoral immunity 
is one strategy against viruses that infect via the mucosal route, including 
influenza virus and coronaviruses (BELSHE et al. 2000; PULENDRAN and 
AHMED 2011). Vaccine-induced antibodies are the first line of defense on the 
mucosal surface and in the blood, with the purpose to control specific pathogens 
before infecting cells and spreading of the virus (PLOTKIN 2008). Moreover, T 
cell response plays an important role in eradicating pathogens which are 
antigenically highly variable (PULENDRAN and AHMED 2011; SALLUSTO et 
al. 2010). Besides, CD4+ T cells support proliferation and expansion of B cells 
to control an ongoing infection (PLOTKIN 2008). The importance of cell-
mediated and humoral immunity was e.g., demonstrated by a phase I clinical 
trial using a recombinant MVA candidate vaccine against MERS-CoV in 2018. 
Koch and colleagues immunized healthy individuals twice over a 28-day interval 
with recombinant MVA expressing MERS-CoV spike protein (MVA-MERS-S). 
Administration of the vaccine was performed with two different doses by using 
the i.m. route. All individuals immunized with the higher dose showed a 
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seroconversion after the booster immunization and more than 90% showed a 
specific T cell response (KOCH et al. 2020). These data are highly notable, as 
the new SARS-CoV-2 is closely related to MERS-CoV and the results of this 
study might help to better understand the immunological pathways of a SARS-
CoV-2 infection. 
 
It is known that a synergetic interaction between B cell and T cell responses is 
needed for protective capacity against poxviruses. In the course of the smallpox 
eradication program, individuals were tested for long-term humoral immunity 
upon vaccination. The amounts of circulating VACV-specific antibodies 
decreased within the first years, but remained stable for several decades 
(AMANNA et al. 2006; el-AD et al. 1990). Moreover, long-living cell-mediated 
immunity could be observed even decades after immunization with stable levels 
of VACV-specific CD4+ T cells and CD8+ T cells (AMARA et al. 2004; 
HAMMARLUND et al. 2003). These findings suggest that a successful vaccine 
should induce a balanced humoral and cell-mediated immunity to protect 
against infectious diseases.  
 
MVA vector platform for construction of a candidate vaccine against 
SARS-CoV-2 
Several new vaccine platforms, including (non)-replicating adenoviral vector 
vaccines or mRNA-based vaccines are currently being tested in preclinical and 
clinical trials against the new SARS-CoV-2. Strong cell-mediated and humoral 
immunity was induced in immunized individuals, but little is known about 
tolerability and long-term immunity of those vaccines (BADEN et al. 2020; CDC 
2021a; CHUNG et al. 2020; LOCHT 2020).  
 
In contrast, the MVA vector platform had been used for decades to develop 
vaccines against various bacterial and viral infections. The replication 
deficiency of MVA in mammalian cells, the capacity to insert long DNA 
sequences into the MVA genome, the gene expression at the cytosolic site and 
the stability of freeze-dried vaccines (GÓMEZ et al. 2011) are some of the great 
advantages of this vector platform. In comparison to MVA, replicative competent 
viruses can be related with severe side effects in elderly or 
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immunocompromised individuals, which raises concerns regarding the usage 
of those vector vaccine platforms. MVA has no survivability in infected host cells 
of mammalian origin, and therefore, a complete clearance of recombinant virus 
and the expressed target antigen can be assumed to occur within days after the 
vaccination (ALTENBURG et al. 2014). Evidence of strong induction of cell-
mediated and humoral immunity had been shown in vitro, in vivo and in several 
clinical trials for MVA-based vaccines (COONEY et al. 1991; GU et al. 1995; 
KOCH et al. 2020; SONG et al. 2013). Humoral immunity is strongly induced by 
expressing the target antigen in its native form (VRIES and RIMMELZWAAN 
2016). 
 
The main advantage of MVA as a vector platform is the ability of living virus to 
infect mainly antigen-presenting cells, thus leading to intracellular expression of 
target antigens (DRAPER and HEENEY 2010). As a result, antigens are 
processed by the infected cells and presented on class I or class II MHC 
molecules, causing strong activation of the CD8+ and the CD4+ T cell 
responses (ALTENBURG et al. 2014; MURPHY et al. 2014). This immunogenic 
capacity of MVA is related to the fact that MVA, in contrast to wild type VACV, 
lacks several immunomodulatory proteins. Multiple intracellular host cell 
detection mechanisms are activated upon infection, resulting in the release of 
various interferons, chemokines and inflammatory cytokines (ALTENBURG et 
al. 2014; DELALOYE et al. 2009). MVA lacks IFN-α/β receptors, causing a type-
I interferon response upon infection. Several in vitro studies with antigen 
presenting cells, such as dendritic cells, revealed high levels of TNF-α, IFN-β 
and IFN-α upon infection with MVA (BLANCHARD et al. 1998; DAI et al. 2014; 
WAIBLER et al. 2007). Besides, MVA lacks a functional receptor for IFN-γ, 
which represents an advantage for using MVA as a vaccine, since IFN-γ is a 
crucial factor for activating cytotoxic T cells (BLANCHARD et al. 1998). 
Moreover, cytotoxic T cells are not the only immune cells that a recruited to the 
infection site. Studies revealed the immigration of other immune cell 
subpopulations such as monocytes, CD4+ T cells and neutrophils (LEHMANN 
et al. 2009). All these findings confirm the favorable immunogenic properties of 
MVA, with the recruitment of a high number of various immune cells to the site 
of administration and the release of high amounts of proinflammatory cytokines 
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(BLANCHARD et al. 1998; WAIBLER et al. 2007).  
 
Challenges for the development of a vaccine against SARS-CoV-2 
Published data from vaccine candidates against SARS-CoV-1 and MERS-CoV 
accelerated the development of vaccines against SARS-CoV-2 (XU et al. 2019). 
Preclinical studies and animal models indicate the following: (i) the spike protein 
is most likely to induce neutralizing antibodies (COLEMAN et al. 2014), (ii) most 
antibodies are directed against the receptor-binding domain (RBD) (DU et al. 
2013), (iii) induced neutralizing antibodies show protective capacity in various 
animal models (rabbits, non-human primates) (MUNSTER et al. 2017), (iv) 
clinical trials with three different vaccines against MERS, a DNA-based vaccine 
(YOON and KIM 2019), a replication-deficient chimpanzee adenovirus (JIA et 
al. 2019) and a MVA-based vaccine (KOCH et al. 2020; SONG et al. 2013), all 
expressing the S protein, induced robust humoral immunity, (v) many vaccine 
candidates induced cell-mediated immunity too, which plays a crucial role in 
viral clearance (ZHAO et al. 2014; ZHAO et al. 2009). Although, the available 
data about vaccine candidates against SARS and MERS show promising 
results, especially when using the spike protein as target antigen, there are 
several obstacles to circumvent.  
 
One important issue to be discussed is the antibody-dependent enhancement 
(ADE) that had been verified for SARS and MERS during in vitro and in vivo 
studies. ADE increases the severity of several infections occurring when 
antibodies at sub-neutralizing levels bind to the viral antigen without inhibiting 
or clearing the infection (LEE et al. 2020). In terms of respiratory infections, ADE 
can lead to an enhanced respiratory infection (ERD). ERD includes antibody 
mediated mechanisms but also non-antibody-based mechanisms such as 
cytokine cascades or cell-mediated immunopathology (GRAHAM 2016; KIM et 
al. 1969; LEE et al. 2020). Antibodies directed against the spike protein have 
been found to mediate ADE in MERS and SARS infected individuals (WANG et 
al. 2014), causing viral infection of normally unaffected macrophages or B cells 
(YIP et al. 2014). Until now, the extent to which ADE might contribute to COVID-
19 immunopathology is still unclear and further evaluations in terms of safety 
are needed when using spike protein-based vaccines (DANDEKAR and 
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PERLMAN 2005; POLAND et al. 2020). Besides, several animal studies of 
candidate vaccines against SARS-CoV-1 and MERS-CoV indicated lung 
pathology upon live virus challenge. Infiltration of eosinophils, elevated Th2 
responses, and augmented infectivity was observed for whole-virus vaccines 
and S protein-based vaccines (BOLLES et al. 2011; DANDEKAR and 
PERLMAN 2005). 
 
Moreover, a known obstacle and acute problem for several RNA viruses is their 
high genomic mutation rate. RNA viruses show a mutation rate of 10*-6 to 10*-
4 substitutions per nucleotide site per cell infection. In contrast, DNA viruses 
show a lower mutation rate with 10*-8 to 10*-6 substitutions per nucleotide site 
per cell infection (PECK and LAURING 2018; VIGNUZZI and ANDINO 2012). 
One explanation for the higher mutation rate found in RNA viruses is the 
expression of their own replication machinery, including the RNA-dependent 
RNA polymerase (RdRp), whereas DNA viruses use the host cell polymerases 
(DUFFY 2018). The RdRp lacks a proofreading activity and thus, mistakes 
during replication are not corrected. Members of the Nidovirales family, 
including SARS-CoV-2, show fewer mutation rates, because of their RdRp-
independent proofreading activity (GORBALENYA et al. 2006; PECK and 
LAURING 2018). The ability to quickly change the genome allows the virus to 
emerge into novel hosts and to escape vaccine-based immunity (VIGNUZZI et 
al. 2005), thus hampering the development of suitable candidate vaccines. As 
mentioned above, many neutralizing antibodies are directed against the RBD. 
Indeed, several mutations within the RBD have been observed for MERS-CoV 
(TAI et al. 2016; TANG et al. 2014), raising concerns about the mutation rate of 
SARS-CoV-2 and the efficacy of S protein-based vaccines. As expected, 
several mutants of SARS-CoV-2 have already been documented to globally 
accumulate in less than 12 months after the outbreak of the pandemic. Three 
of these new variants are notable, as they are associated with more severe 
outcome of COVID-19 and increased infectivity of SARS-CoV-2 (CDC 2021a; 
WHO 2020). The first variant, B.1.1.7, which was first detected in the United 
Stated of America and is predominantly prevalent in the United Kingdom, 
carries a large number of different mutations and recent studies indicate higher 
risk of death compared to other variants upon infection (PUBLIC HEALTH 
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ENGLAND 2021). The second variant, B.1.351, shares mutations with variant 
B.1.1.7 and is broadly distributed in South Africa (WHO 2020). The third variant, 
P1, was first described in Brazil (TOOVEY et al. 2021), and is characterized by 
17 unique mutations. Three of these mutations are found within the RBD 
(K417T, E484K, N501Y) and non-peer reviewed publication preprints indicate 
that this variant decreases the ability of antibodies to recognize and neutralize 
SARS-CoV-2 (PUBLIC HEALTH ENGLAND 2021). Two specific mutations, 
N501Y and D614G (VOLZ et al. 2020), are shared by all three variants with the 
latter causing an increased infectivity of the virus (KORBER et al. 2020; 
YURKOVETSKIY et al. 2020). The prevalence of new variants raises the 
concern about the efficacy of SARS-CoV-2 vaccines currently being tested in 
preclinical and clinical trials. Hence, the vaccine targeting the full-length spike 
protein as used in the three licensed vaccines and our MVA-SARS-CoV-2-S 
vaccine, might be more effective than RBD-based vaccines. 
 
Future prospective 
New SARS-CoV-2 is still present and only a suitable vaccine will combat the 
global pandemic. With the prevalence of new and more infectious variants of 
the virus, mainly focusing on the S protein as target antigen used for vaccine 
development may need to be reconsidered. Nevertheless, several vaccine 
candidates based on different platforms are currently being tested in preclinical 
and clinical trials and show promising data for induction of cell-mediated and 
humoral immunity. The here descripted recombinant MVA expressing the full-
length SARS-CoV-2 spike protein shows convincing data in terms of genetic 
stability, safety and tolerability upon vaccination and strong induction of CD8+ 
T cell responses as well as high antibody responses. Future work would include 
a more detailed analysis of the immunogenetic capacity of MVA-SARS-CoV-2-
S in preclinical and clinical trials. 
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VIII. SUMMARY 
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the 
causative agent of COVID-19 and led to a global pandemic in 2020. Globally, 
millions of people are infected with several thousands of individuals dying every 
day because of COVID-19. Up to now, no treatments are available and the most 
promising option to eradicate SARS-CoV-2 is a successful vaccine. Many 
researchers worldwide are working on different vaccines against SARS-CoV-2, 
with three different vaccines already licensed for immunization in Europe. 
Nevertheless, little is known about long-living immunity, tolerability or protective 
capacity of these new platform vaccines. This fact as well as the observed 
prevalence of new and more infectious virus variants strengthens the necessity 
of developing immunogenic and broad-reactive candidate vaccines of different 
origin. 
 
In this work, the construction and preclinical characterization of recombinant 
MVA expressing the full-length SARS-CoV-2 spike protein is described. In vitro 
characterization including high genetic stability, replicative deficiency in 
mammalian cells, combined with a stable and robust expression of the spike 
antigen, revealed first promising data for further in vivo testing. BALB/c mice 
developed a robust S antigen specific CD8+ T cell response even after one 
immunization, that could be increased after a second immunization. Vaccinated 
mice using a prime-boost schedule over a 21-day interval showed elevated 
levels of serum antibodies against the spike protein. In addition, those serum 
antibodies can neutralize SARS-CoV-2 in the respective assay. Prime-boost 
vaccination with MVA-SARS-CoV-2-S could protect mice transduced with a 
human ACE2-expressing adenovirus from an infection with SARS-CoV-2. 
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IX. ZUSAMMENFASSUNG 
Das severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) führte im 
Jahr 2020 zur globalen Pandemie COVID-19. Weltweit infizierten sich bereits 
mehrere Millionen Menschen mit dem Virus und Tausende Infizierte sterben 
täglich mit oder an COVID-19. Da es bis jetzt keine wirksamen 
Behandlungsmöglichkeiten gibt, scheint eine Impfung die einzige Möglichkeit 
zu sein, die globale Pandemie einzudämmen. Unzählige Wissenschaftler 
arbeiten unter Hochdruck an der Entwicklung neuer Impfstoffe gegen das 
SARS-CoV-2 und mit Ende Februar 2021 gibt es in Europa bereits drei 
zugelassene Impfstoffe. Jedoch ist wenig bekannt über Langzeit-
Immunogenität, Verträglichkeit oder Schutzwirkung dieser neuen Impfstoffe 
und das Auftreten neuer, noch infektiöserer Virus Varianten verdeutlichen die 
Notwendigkeit mehrerer wirksamer Impfstoffe. 
 
In dieser Arbeit wurde die Konstruktion und präklinische Charakterisierung 
eines rekombinanten MVA, das das native SARS-CoV-2 Spike Protein 
exprimiert, beschrieben. Eine in-vitro Charakterisierung in Bezug auf 
genetische Stabilität, der Unfähigkeit von MVA sich auf Säugerzellen zu 
replizieren, sowie eine stabile Expression des Spike Proteins zeigten erste, 
vielversprechende Ergebnisse zur weiteren Testung in vivo. BALB/c Mäuse 
zeigten eine robuste S Antigen spezifische CD8+ T Zellantwort bereits nach 
einer Immunisierung, die nach einer zweiten Immunisierung erhöht werden 
konnte. BALB/c Mäuse, die in einem 21- Tage Intervall immunisiert wurden, 
wiesen erhöhte Serumantikörper gegen das Spike Protein auf und darüber 
hinaus konnte mit einem entsprechenden Assay eine neutralisierende Wirkung 
gegen das SARS-CoV-2 demonstriert werden. Immunisierte BALB/c Mäuse, 
die mit einem humanen ACE2-exprimierenden Adenovirus transduziert wurden, 
konnten vor einer Infektion mit SARS-CoV-2 geschützt werden.
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XI. APPENDIX 
1.1. Chemicals 
Chemical Supplier 
2-Propanol ≥ 99.8% Carl Roth, Karlsruhe, Germany 
Acetone ≥ 99.5% Carl Roth, Karlsruhe, Germany 
Albumine, IgG-free Carl Roth, Karlsruhe, Germany 
Biozym LE Agarose Biozym Scientific, Hessisch 
Oldendorf, Germany 
Brefeldin A Biolegend, London, United Kingdom 
cOMPLETE, EDTA free Roche Diagnostics, Mannheim, 
Germany 
DAPI Thermo Fisher Scientific, Planegg, 
Germany 
DMSO Sigma-Aldrich, Taufkirchen, 
Germany 
Ethanol 96%,  Carl Roth, Karlsruhe, Germany 
GelRed Nucleic Acid Gel Stain, 10 000x Biozol GmbH, Eching, Germany 
Glycin PanReac AppliChem, Darmstadt, 
Germany 
KPL TrueBlueTM Peroxidase Substrate HiSS Diagnostics GmbH, Freiburg im 
Breigau, Germany 
Methanol ≥ 99% Carl Roth, Karlsruhe, Germany 
MACSQuant FACS buffer Milenyi Biotec, Bergisch Gladbach, 
Germany 
MACSQuant Perm buffer Milenyi Biotec, Bergisch Gladbach, 
Germany 
MACSQuant Wash buffer Milenyi Biotec, Bergisch Gladbach, 
Germany 
Nonfat dried milk powder PanReac AppliChem, Darmstadt, 
Germany 
Red Blood Cell Lysing Buffer Hybri-Mix Sigma-Aldrich, Taufkirchen, 
Germany 
Roti-Load 1, reducing, 4x Carl Roth, Karlsruhe, Germany 
Stop Reagent for ELISA Sigma-Aldrich, Taufkirchen, 
Germany 
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Sucrose Sigma-Aldrich, Taufkirchen, 
Germany 
TMB for ELISA Sigma-Aldrich, Taufkirchen, 
Germany 
Tris-Ultrapure PanReac AppliChem, Darmstadt, 
Germany 
Triton-X100 Sigma-Aldrich, Taufkirchen, 
Germany 
Trypan blue Sigma-Aldrich, Taufkirchen, 
Germany 
Tween20 Sigma-Aldrich, Taufkirchen, 
Germany 
Zombie dye Biolegend, London, United Kingdom 
 
1.2. Consumables 
Material Supplier 
6-well tissue culture plates Sarstedt, Nümbrecht, Germany 
24-well tissue culture plates Sarstedt, Nümbrecht, Germany 
96-well tissue culture plates Sarstedt, Nümbrecht, Germany 
Cover slips Thermo Fisher Scientific, Planegg, 
Germany 
CryoPure tube Sarstedt, Nümbrecht, Germany 
Disposal bag Sarstedt, Nümbrecht, Germany 
Ep T.I.P.S Standard 20-300 µl Eppendorf AG, Hamburg, Germany 
Filter tips (20 µl) Sarstedt, Nümbrecht, Germany 
Filter tips (100 µl) Sarstedt, Nümbrecht, Germany 
Filter tips (200 µl) Sarstedt, Nümbrecht, Germany 
Filtopur S0.45 Sarstedt, Nümbrecht, Germany 
Microtest plate 96-well  Sarstedt, Nümbrecht, Germany 
MiniCollect vials  Greiner Bio-One, Frickenhausen, Germany 
Nitrocelluose Blotting Membrane GE Healthcare Europe, Freiburg, Germany 
Nunc-Immuno Plate Thermo Fisher Scientific, Planegg, 
Germany 
SafeSeal reaction tube 1.5 ml Sarstedt, Nümbrecht, Germany 
SafeSeal reaction tube 2 ml Sarstedt, Nümbrecht, Germany 
Serological pipette 5 ml Sarstedt, Nümbrecht, Germany 
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Serological pipette 10 ml Sarstedt, Nümbrecht, Germany 
Serological pipette 25 ml Sarstedt, Nümbrecht, Germany 
TC flask 25 Sarstedt, Nümbrecht, Germany 
TC flask 75 Sarstedt, Nümbrecht, Germany 
TC flask 175  Sarstedt, Nümbrecht, Germany 
Tube 15 ml Sarstedt, Nümbrecht, Germany 
Tube 50 ml Sarstedt, Nümbrecht, Germany 
1.3. Laboratory equipment 
Laboratory equipment Supplier 
A.EL.VIS Universal plate reader V3.0 A.EL.VIS GmbH, Hannover, Germany 
Avanti J-26 XP Centrifuge  Beckmann Coulter, Krefeld, Germany 
Biofuge fresco Heraeus, Hanau, Germany 
Centrifuge 5424 Eppendorf AG, Hamburg, Germany 
ChemiDocTMMP, Imaging System  Bio-Rad, Munich, Germany 
FACS Calibur cytofluorometer  
 
Becton Dickinson, Heidelberg,  
Germany 
Galaxy 170S Incubator New Brunswick (Eppendorf), Hamburg, 
Germany 
KEYENCE BZ-X710 All-in one 
Fluorescence Microscope  
KEYENCE Deutschland GmbH, 
NeuIsenburg, Germany 
Microplate reader Sunrise Tecan Trading AG, Männedorf, 
Switzerland 
MJ Research PTC-200 Peltier Thermal 
Cycler 
GMI, Ramsey, USA 
Olympus CKX41  Olympus Life Sciences, Hamburg, 
Germany 
OptimaTMLE-80K Ultracentrifuge  Beckman Coulter, Krefeld, Germany 
Sonoplus Bandelin electronic, Berlin, Germany 
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1.4. DNA and protein marker 
Material Supplier 
1 kb DNA ladder  New England Biolabs, Frankfurt, 
Germany 
Pageruler prestained protein ladder New England Biolabs, Frankfurt, 
Germany 
 
1.5. Commercial Kits 
Material Supplier 
2.5 mM dNTP Mix Invitrogen, Darmstadt, Germany 
MINI-Protean TGX Bio-Rad, Feldkirchen, Germany 
Mouse IFN-y ELISpotPlus kit (ALP) Mabtech, Nacka Strand, Germany 
NucleoBond Xtra Midi Macherey-Nagel, Düren, Germany 
NucleoSpin Blood QuickPure Macherey-Nagel, Düren, Germany 
NucleoSpin Gel and PCR Clean-up Macherey-Nagel, Düren, Germany 
NucleoSpin Plasmid Macherey-Nagel, Düren, Germany 
OneStep RT-PCR Kit Qiagen, Hilden, Germany 
PNGase F New England Biolabs, Frankfurt, 
Germany 
RNeasy Mini kit Qiagen, Hilden, Germany 
SuperSignal West Dura Extended 
Duration Substrate 
Thermo Fisher Scientific, Planegg, 
Germany 
Taq DNA Polymerase Invitrogen, Darmstadt, Germany 
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1.6. Media and supplements for cell culture 
Material Supplier 
DMEM Sigma-Aldrich, Taufkirchen, Germany 
DMEM (high glucose) Sigma-Aldrich, Taufkirchen, Germany 
DPBS  Thermo Fisher Scientific, Planegg, 
Germany 
FBS Thermo Fisher Scientific, Planegg, 
Germany  
HEPES solution Sigma-Aldrich, Taufkirchen, Germany 
L-Glutamine  Thermo Fisher Scientific, Planegg, 
Germany 
MEM Sigma-Aldrich, Taufkirchen, Germany 
MEM non-essential amino acid solution  Sigma-Aldrich, Taufkirchen, Germany 
Penicillin-Streptomycin Sigma-Aldrich, Taufkirchen, Germany 
RPMI-1640 medium Sigma-Aldrich, Taufkirchen, Germany 
SFP eggs VALO BioMedia GmbH, Cuxhaven, 
Germany 
TrypLE™ Select Enzym  Thermo Fisher Scientific, Planegg, 
Germany 
VP-SFM  Thermo Fisher Scientific, Planegg, 
Germany 
 
1.7. Buffer  
Lysis buffer 
1% Triton X-100 
25 mM Tris 
1 M NaCl 
Transfer buffer (conc.) 
24 g Tris 
114,6 g Glycin 
ad 1l ddH2O 
5x Running buffer  
72.5 g Glycin 
15,2 g Tris 
25 ml 20% SDS 
ad 1l ddH2O 
Transfer buffer (working solution) 
80 ml Towbin buffer (conc.) 
200 ml Methanol 
ad 1 l ddH2O 
Vaccine buffer (pH=7.4) 
10 mM Tris 
140 mM NaCl 
50x TAE buffer (pH= 7.4) 
242 g Tris 
57.1 ml acetic acid glacial 
18.6 g EDTA 
XI. Appendix 104 
ad 1l ddH2O 
LB-Medium (pH= 7.5) 
5 g NaCl 
5 g Yeast extract  
10 g Trypton 
ad 1l ddH2O 
LB-agar 
1,5% Agar-Agar in LB-Medium 
10x PBS 
2 g KCl 
2 g KH2PO4 
80 g NaCl 
11.5 g Na2HPO4 
ad 1l ddH2O 
 
 
1.8. Software 
Adobe Reader Adobe Systems, San Jose, USA 
A.EL.VIS V6.1 A.EL.VIS GmbH, Hannover, Germany 
BioRender BioRender, Toronto, USA 
DNASTAR Lasergene  DNASTAR, Inc., Madison, Wisconsin, USA 
FlowJo LLC BD Life Sciences, Ashland, USA 
GraphPad prism GraphPad Software, San Diego, USA 
Image Lab 5.0 Software  Bio-Rad, Feldkirchen, Germany 
Microsoft Office 2016 Microsoft Corp., Redmond, USA 
NetNGlyc 1.0 Server http://www.cbs.dtu.dk/services/NetNGlyc/ 
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